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Abstract 
 
Chronic diabetic complications are significant causes of morbidity. In 
diabetes, as the cellular changes are similar to aging, we investigated the role of 
sirtuins (SIRTs) in chronic diabetic complications. 
We examined glucose and aging-induced changes in the endothelial cells 
(ECs), the primary targets of chronic diabetic complications. ECs in high glucose 
showed evidences of early senescence, being more pronounced in microvascular 
ECs in association with decreased SIRT1 and FOXO1-dependent reduction in 
antioxidant gene expressions. A regulatory relationship of deacetylator SIRT1 and 
histone acetylator p300 was identified. Renal and retinal tissues of diabetic animals 
showed similar results.  
Having established such changes, we investigated microRNA-mediated 
regulation of glucose-induced SIRT1 alteration. We examined the effect of miRNA-
195 (miR-195), a SIRT1-targeting miRNA, on the development of diabetes-induced 
changes in the ECs and retina. High glucose caused increased miR-195 levels and 
decreased SIRT1 expression in the ECs. We showed that miR-195 binds to the 3′ 
untranslated region of SIRT1 and transfection with miR-195 antagomir or over-
expression of SIRT1 prevented above changes, whereas transfection with miR-195 
mimic produced glucose-like effects.  miR-195 expression was upregulated in 
retinas of diabetic rats and intravitreal injection of miR-195 antagomir ameliorated  
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reduction of SIRT1 and associated changes in diabetes. These studies identified a 
novel mechanism whereby miR-195 regulates SIRT1-mediated tissue damage. 
Based on results above, we examined whether in diabetes, SIRT1 alteration 
mediate specific effects in the target organs affected in diabetic complications. We 
focused on endothelin1 (ET-1) and transforming growth factor beta 1 (TGF-β1), two 
key mediators of increased extracellular matrix protein production. In ECs exposed 
to high glucose, there were increased ET-1, TGF-β1, p300 and collagen Iα(I) along 
with SIRT1 downregulation. Such changes were corrected by knockdown of p300 or 
SIRT1 overexpression. In the kidneys and retina of diabetic mice, similar 
biochemical alterations were seen along with increased vascular permeability in 
retina and microalbuminuria of the kidney. In the transgenic animals with SIRT1 
overexpression, such diabetes-induced abnormalities were prevented.  
Overall these studies identified SIRT1-mediated accelerated aging 
phenomena in diabetes causing cellular injuries leading to renal and retinal injury. 
SIRT1 may lend itself as a target to prevent organ damages in diabetes. 
 
Keywords 
Endothelial cells, SIRT1, FOXO1, p300, miR-195, ET-1, TGFβ-1, FN, Diabetic 
complications, Diabetic retinopathy, Diabetic nephropathy, Cellular aging 
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Chapter 1  
1 Introduction 
 
1.1 Diabetes mellitus (epidemiology and its economic impact)  
Diabetes mellitus (DM) is a multifactorial and genetically heterogeneous 
disease which is characterized by impaired glucose homeostasis, reduced insulin 
activity and insulin resistance leading to elevated blood glucose levels [1, 2]. The 
elevated blood glucose causes symptoms of frequent urination, increased thirst 
and hunger in patients [1, 2].  
As of 2013 it is estimated that 382 million people worldwide have diabetes 
[3-8].  This is affecting in equal rates in both men and women [3-8]. Diabetes 
related complications are the 8th leading cause of death worldwide and half the 
people who die from diabetic complications are under the age of 60 [3-8]. By 
2035, the number of people with diabetes is predicted to rise to 592 million [3-8]. 
Diabetes occurs throughout the world, but is more predominant in the developed 
countries (specially type 2). However the greatest increase in rates is expected to 
occur in the developing countries in Asia and Africa [3-8]. Such increase in rates 
in developing countries is probably due to urbanization and lifestyle changes, 
specially a western-style diet. This suggests an environmental effect, but there is 
little understanding of such mechanism at present [3-8]. According to 
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International Diabetes Federation, the economic cost of diabetes globally in 2013 
was estimated to be $548 billion [8]. In Canada, according to data from the Public 
Health Agency (PHA) of Canada's Economic burden of illness in Canada (EBIC) 
the estimated cost for diabetes cares is above $7 billion per year [9, 10].  
There are three main types of DM. Type 1 DM, type 2 DM and gestational 
DM. 
 1.1.1 Type 1 DM 
Type I DM results from the body's failure to produce insulin and was 
previously referred to as insulin-dependent diabetes mellitus (IDDM) or juvenile 
diabetes [1, 2]. Type 1 DM is caused by autoimmune destruction of the insulin 
producing beta cells in the pancreatic islets. The subsequent loss of insulin 
causes hyperglycemia [1, 2]. These patients require exogenous insulin injections 
for survival [1, 2]. 
1.1.2 Type 2 DM 
Type 2 DM (previously known as non-insulin dependent diabetes mellitus, 
NIDDM) results from resistance to insulin [1, 2]. This is a condition in which cells 
fail to use insulin properly and sometimes also with an absolute insulin deficiency 
[1, 2]. This typically develops in adults. The etiology of type 2 diabetes is 
unknown. However, physiological, genetic and environmental factors such as 
obesity, family history, pollution are known to predispose someone to this 
disease [1-10]. Most of the population with diabetes belongs to this group [1-10]. 
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1.1.3 Gestational DM 
Gestational diabetes occurs in some pregnant women, without a previous 
history of diabetes during third trimester. This is caused by impaired function of 
the insulin receptors due to interference with pregnancy related hormones 
leading to high blood glucose level [1, 2]. GDM usually resolves after the birth of 
the baby however these patients have a high risk of developing type 2 DM later 
in life [1, 2]. 
1.2 Diabetic complications 
Despite the etiologic type of diabetes, chronic hyperglycemia in advanced 
form of the disease causes serious health problems affecting multiple organs 
causing conditions such as retinopathy, nephropathy, cardiomyopathy, and 
neuropathy [11]. Such damages to the eye, kidney, heart and nerves are caused 
by micro- and macro vascular dysfunctions [12, 13]. Hyperglycemia causes 
structural and functional alteration to the vascular system thus affecting the target 
organs [11-13]. In the present study we have focused on diabetic retinopathy and 
nephropathy. 
1.2.1 Diabetic retinopathy (DR) 
DR is a slowly progressive disease of the eye which if left untreated can 
cause blindness [14]. Hyperglycemia induced oxidative stress in diabetes is the 
primary stimuli that triggers a cascade of events leading to DR [14-17]. DR 
causes vascular structural and functional changes in the retina. DR is classified 
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into two phases, non-proliferative diabetic retinopathy (NPDR) and proliferative 
diabetic retinopathy (PDR) [14-17]. In NPDR micro vessels in the retina become 
weak and leaky forming microaneurysms and causing retinal hemorrhages, 
which leads to decreased vision [14-16]. A characteristic feature of PDR is 
neovascularization in which new blood vessels grow to reperfuse ischemic areas 
of the retina [14-16]. These new fragile blood vessels hemorrhage easily and in 
advanced stage cause scarring, tractional retinal detachment and eventually 
blindness [14-16].  
1.2.2 Diabetic nephropathy (DN) 
DN is a progressive kidney disease caused by microangiopathy of the 
kidney glomeruli [11, 12]. DN is characterized by nephrotic syndrome (increased 
permeability of the capillary wall causing microalbuminuria, hypoalbuminemia, 
hyperlipidemia and edema) and diffuse glomerulosclerosis [11, 12]. It is a major 
cause of dialysis in Western countries [1-10]. In spite of the improvements in 
therapeutic modalities, diabetes and its complications account for significant 
morbidity and mortality throughout the world [1-10]. The root cause of all vascular 
damage in chronic diabetic complication is endothelial cell (EC) dysfunction [11-
13]. 
1.3 Endothelial cell dysfunction 
Endothelial dysfunction (ED) is the initiating and perpetuating factor in the 
development of vascular complications [11-13]. Loss of proper endothelial 
function is a characteristic feature of several vascular diseases. It is often 
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regarded as a key early event in the development of atherosclerosis during early 
stages of diabetes [11-13, 18, 19]. In diabetes, the most prevailing mechanism of 
endothelial dysfunction is an increase in oxidative stress which can alter cellular 
homeostasis via several mechanisms [12, 13]. In response to high ambient 
glucose levels, several metabolic pathways get activated. These include the 
polyol pathway, non-enzymatic formation of advanced glycation end-product 
(AGE), activation of protein kinase C (PKC) and hexosamine pathway [12, 13]. It 
has been shown that in diabetes hyperglycemia increases the proton gradient in 
the mitochondrial electron transport chain (ETC) causing oxidative stress and 
overproduction of superoxides [11-13]. Ultimately these pathways lead to an 
increased production of vasoactive factors (VEGF, ET-1), growth factors (TGF-
β1) and cytokines [11-14, 18, 19]. These factors lead to an alteration of 
hemodynamic parameters such as blood flow and permeability [11-14, 18, 19]. In 
addition, autocrine and paracrine properties of these factors lead to increased 
production of extracellular matrix (ECM) proteins [20-22]. Imbalance in the 
production and the degradation of ECM proteins like fibronectin (FN) and 
collagen lead to structural alterations such as basement membrane (BM) 
thickening [11-13, 20-22].  Outlined below are some specific changes seen in 
diabetic complications that are of interest in this research. 
1.4 Alteration of extra cellular matrix proteins 
The mechanism of increased ECM protein synthesis is of great interest for 
the development of therapeutic modalities, as ECM protein deposition remains 
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the single most common finding in chronic diabetes [11]. Increased syntheses of 
ECM proteins such as FN and collagen have been demonstrated in diabetic 
angiopathy [19-22]. FN is a high molecular weight glycoprotein and a major 
component of the ECM proteins. FN plays an important role in various cellular 
events such as adhesion, growth, migration, differentiation and is crucial during 
embryogenesis and wound healing [23]. Altered FN expression, organization and 
degradation have been found to be associated with a number of pathologies 
including fibrosis and cancer [23]. Our lab has shown that diabetes leads to 
increased FN in all target organs of diabetic complications [11, 19-22]. We have 
also shown that EDB+FN (an embryonic splice variant of FN, absent in adult 
tissues) is upregulated in the ECs and retinas in diabetes [24]. EDB+FN 
upregulation is dependent on ET-1 and TGF-β1 and provides outside-in 
signalling, causing EC proliferation and differentiation [24]. EDB+FN gene 
silencing prevented glucose-induced VEGF expression and reduced the 
proliferative capacity of ECs [24]. 
Expression of FN in ECs exposed to high glucose is regulated by the 
activation of transcription factor NF-κB [25]. NF-κB plays a pivotal role in the 
regulation of several genes. In a non-stimulated cell, NF-κB dimers are 
sequestered in the cytoplasm bound to a group of inhibitor proteins named IκB. 
There are two classes of NF-κB (P50/52 or P65/relB c-rel) [26]. The main form of 
activated NF-κB is heterodimer P50/P65 [26]. Upon stimulation, IκB is 
phosphorylated by IKK and eventually degraded leaving NF-κB free to be 
translocated to nucleus [26]. NF-κB in nucleus binds to the promoters of specific 
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genes affecting its expression [26]. Function of transcription factor(s) such as NF-
κB depends on transcriptional co-activators. For example, association of NF-κB 
with transcriptional co-activators p300, is essential, and without such association, 
transcription factors remains silent, even following nuclear translocation [25, 26]. 
1.5 p300 production and histone acetylation in diabetes 
EP300 or p300 is a transcriptional coactivator protein (part of the p300-
CBP coactivator family) which interacts with numerous transcription factors to 
increase the expression of various target genes [27]. It has five protein 
interaction domain and an intrinsic histone acetyltransferase (HAT) domain [27]. 
P300 regulates gene expression by relaxing the chromatin structure at the gene 
promoter through their HAT activity [27]. P300 also increase gene expression by 
acting as an adaptor molecule or recruiting the basal transcriptional machinery to 
the promoter [27]. Mutation in p300 gene causes severe mental retardation 
whereas loss of one copy of the genes prevents normal development. P300 
mutation has also been found to be associated with several types of cancers 
[27]. P300 has been found to be increased in response to hyperglycemia in ECs 
and tissues in diabetes [28]. It regulates AP-1 and NF-kB [28].  Studies in our lab 
showed increased p300 production in hyperglycemia leads to augmented histone 
acetylation, activation of multiple transcription factors and increased expression 
of vasoactive factors and ECM proteins in the ECs [28-30]. P300 plays a vital 
role on FN, ET-1 and VEGF overexpression in the cardiac, retinal, and renal 
tissue in diabetes [28-30]. DNA repair enzymes ERCC1 (DNA Excision Repair 
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Protein 1) and ERCC4 (DNA Repair Endonuclease XPF) increase FN expression 
in a p300-dependent manner [31]. MAPK, PKC, and Akt pathways have been 
shown to mediate overexpression of p300 in response to oxidative stress [28-31]. 
Inhibitors of p300 have potential therapeutic value. Silencing or inhibition of p300 
ameliorated the structural and functional damages of diabetic nephropathy and 
cardiomyopathy [28-31]. The HAT activity of p300 is balanced by histone 
deacetylases (HDACs). By deacetylating histones HDACs move chromatin to a 
more repressed state controlling gene expressions [28]. Three classes of HDACs 
have been identified. Class I HDACs reside in the nucleus, while class II HDACs 
shuttle between the nucleus and cytoplasm. Sirtuins are class III HDACs [32-38]. 
1.6 SIRTUINS 
Silent information regulator proteins or sirtuins (SIRTs) are class III 
histone deacetylases (HDACs) and known to regulate epigenetic gene silencing 
and suppress recombination of rDNA [32-38]. Initially they were identified in 
yeast and were found to increase lifespan hence also known as the longevity 
gene. In mammals they have a range of molecular functions and have emerged 
as important proteins in aging, calorie restriction, inflammation, stress resistance, 
cellular differentiation, DNA repair and metabolic regulation [32-38]. SIRTs have 
a conserved 275 amino acid catalytic core domain and a unique N-terminal 
and/or C-terminal sequences. SIRTs deacetylase not only histones, but also 
many cellular proteins and transcription factors [38]. In addition to protein 
deacetylation, studies have shown that some SIRTs also function as intracellular 
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regulatory proteins with mono ADP ribosyltransferase activity [32-38]. Unlike 
other known protein deacetylases, which only hydrolyze acetyl-lysine residues, 
sirtuins couple lysine deacetylation to NAD hydrolysis yielding O-acetyl-ADP-
ribose, the deacetylated substrate and NAD (itself an inhibitor of SIRT activity) 
[38]. SIRTs require nicotinamide adenine dinucleotide (NAD+) for their 
deacetylase or ADP-ribosyl transferase activity, linking their function strictly to 
cellular energy levels [32-38]. In chronic diabetic complications, lack of available 
NAD+ due to activation of polyol pathway and PARP (poly ADP ribose 
polymerase), further reduces activity of SIRTs [32-38]. Furthermore glucose 
induced reduced nicotinamidephosphoribosyl transferase (Nampt) also 
decreases available NAD+ and reduce SIRT activity [32-38]. In mammals, the 
SIRTs represent a small gene family with seven members designated SIRT1 
through SIRT7 localizing in nucleus (1, 2, 6, 7), cytoplasm (1, 2) and the 
mitochondria (3, 4, 5).  SIRT1, SIRT6, and SIRT7 are localized in the nucleus, 
where they act to deacetylate histones thereby influencing gene expression 
epigenetically [32-38]. SIRT1 further deacetylates specific transcription factors 
and enzymes to influence their activities. SIRT2 was originally described as a 
cytosolic molecule; however recent data show that SIRT2 is also found in the 
nucleus where it functions to modulate cell cycle control. SIRT3, SIRT4, and 
SIRT5 are localized in mitochondria regulating the activities of metabolic 
enzymes and moderate oxidative stress in this organelle [32-38]. In general, 
SIRT3–5 switch cells to favor mitochondrial oxidative metabolism, along with the 
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induction of accompanying stress tolerance [32-38]. In this study we have 
examined the role of SIRT1 in diabetic complications. 
1.6.1 SIRT1 
SIRT1 the leading member of the SIRT family resides both in the nucleus 
and in the cytoplasm [39]. It has been found to regulate many central pathways 
related to cellular senescence, metabolism, inflammation, insulin secretion, 
tumorigenesis, cell cycle regulation, stress resistance and various diseases [39-
43]. SIRT1 plays a critical role in metabolic health by deacetylating many target 
proteins in numerous tissues, including liver, heart, muscle, adipose tissue and 
endothelium [39-43]. SIRT1 also exerts important systemic effects via the 
hypothalamus [44].  In response to different environmental stimuli, SIRT1 links 
the cellular metabolic status to the chromatin structure and the regulation of gene 
expression, thus modulating a variety of cellular processes such as energy 
metabolism and stress response [44]. Current studies have shown that SIRT1 
controls both glucose and lipid metabolism in the liver, promotes mobilization of 
fat and stimulates differentiation of brown and white adipose tissue, controls 
pancreatic insulin secretion, influences obesity-induced inflammation in 
macrophages and modulates the activity of circadian clock in metabolic tissues 
[39-44]. 
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1.6.1.1 SIRT1 in pancreas  
SIRT1 has been shown to be a positive regulator for pancreatic insulin 
secretion, which consecutively triggers glucose uptake and utilization [45]. 
Increased dosage of SIRT1 in mice pancreatic beta cells improve glucose 
tolerance and enhances insulin secretion [45-47]. Deletion of SIRT1 impairs 
glucose-stimulated insulin secretion [45, 46]. SIRT1 has been shown to promote 
insulin secretion through transcriptional repression of uncoupling protein 2 
(UCP2) [46]. Activation of SIRT1 in animals protects against obesity and insulin 
resistance [48]. Overexpression of SIRT1 has been found to have a protective 
effect against glucose intolerance [49-52].  
1.6.1.2 SIRT1 in adipose tissues 
SIRT1 has been shown to repress PPARγ in white adipose tissue (WAT) 
suppressing the expression of adipose tissue marker protein such as aP2 [53]. 
Genetic ablation of SIRT1 in adipose tissues leads to increased adiposity and 
insulin resistance [54]. Treatment of mice with SIRT1 activator resveratrol has 
been shown to protect against obesity and metabolic derangements [47-52]. In 
addition to WAT, studies have also implicated a role of SIRT1 in the 
differentiation and function of brown adipose tissue (BAT) [55]. SIRT1 promote 
BAT differentiation through repression of the MyoD-mediated myogenic gene 
expression and PGC-1α mediated mitochondrial gene expression [55]. SIRT1 in 
propiomelanocortin (POMC) neurons selectively control perigonadal WAT to BAT 
like remodeling to increase energy expenditure in female mice [56]. A recent 
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study indicates that SIRT1 can also regulate the brown remodeling of WAT in 
response to cold exposure by deacetylation of PPARγ [57].  
1.6.1.3 SIRT1 in the hypothalamus 
Recent studies have shown that both calorie restriction (CR) and fasting 
enhance SIRT1 expression and activity in the hypothalamus [58]. Mice lacking 
SIRT1 in the brain fail to mediate changes in pituitary signaling and physical 
activity in response to CR [58, 59]. Brain-specific SIRT1 transgenic mice display 
enhanced neural activity in the hypothalamus [58-60]. Inhibition of hypothalamic 
SIRT1 activity has been found to increase acetylation of FOXO1 (forkhead box 
protein O1), leading to increased POMC and decreased AgRP (agouti-related 
peptide) expressions, thereby decreasing food intake and weight gain [61]. AgRP 
specific deletion of SIRT1 alleviates the inhibitory tone on the POMC neurons 
causing decreased food intake and body weight [61]. Deletion of SIRT1 in POMC 
neurons in mice causes a blunted response to leptin signaling and reduced 
energy expenditure leading to obesity [61]. Intra-cerebro-ventricular treatment of 
resveratrol, a known SIRT1 activator normalizes hyperglycemia and improves 
hyperinsulinemia in obese mice with diabetes [62]. 
1.6.1.4 SIRT1 in hepatic glucose and lipid metabolism 
SIRT1 is an important regulator of hepatic glucose metabolism [63]. 
Hepatic SIRT1 is a key modulator of gluconeogenesis in response to fasting [64]. 
Fasting increases SIRT1-mediated deacetylation and activation of PGC-1α, 
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resulting in increased fatty acid oxidation and improved glucose homeostasis 
[63]. SIRT1 also plays an important role in hepatic fatty acid metabolism [65]. 
Adenoviral knockdown of SIRT1 reduces expression of fatty acid β-oxidation 
genes in the liver [65]. Specific deletion of the exon 4 of the mouse hepatic 
SIRT1 gene, results in an inactive SIRT1 protein which impairs fatty acid β-
oxidation through the PPARα/PGC-1α pathway [66, 67]. This increases the 
susceptibility of mice to dyslipidemia, hepatic steatosis, inflammation, and 
endoplasmic reticulum (ER) stress [68]. Overexpression of SIRT1 in mice liver 
attenuates hepatic steatosis and ER stress restoring glucose homeostasis [68]. 
SIRT1 also regulates hepatic cholesterol and bile acid through direct modulation 
of the liver X receptors (LXRs) and farnesoid X receptor (FXR) [69-71]. Systemic 
deletion of SIRT1 in mice results in decreased serum high density lipoprotein 
(HDL) levels [72]. SIRT1 also regulate hepatic lipid metabolism through 
deacetylation of SREBPs (sterol regulatory element binding proteins), critical 
regulators of lipid and cholesterol genesis [73]. 
1.6.1.5 SIRT1 in inflammation 
Researchers have identified SIRT1 as an important repressor of 
inflammation in multiple tissues and cells including the macrophages [74-76]. In 
mice, overexpression of SIRT1 causes suppression of the inflammatory response 
and insufficiency of SIRT1 induces systemic inflammation [77]. Deletion of SIRT1 
in hepatocytes results in increased local inflammation [78]. Several recent 
studies indicate that SIRT1 suppress the activity of NF-κB, the central regulator 
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of cellular inflammatory response [79, 80]. SIRT1 deacetylates the RelA/p65 
subunit of NF-κB, leading to decreases in the NF-kB transcriptional activity thus 
reducing expression of pro-inflammatory cytokines [80]. Overexpression of 
SIRT1 in mice leads to reduced NF-κB activity, while knockdown of SIRT1 in the 
mouse macrophages increases LPS-stimulated TNFα (tumor necrosis factor α) 
secretion [79, 80]. Moreover, smoking decreases SIRT1 levels in human 
macrophages leading to increased activation of NF-κB mediated pro-
inflammatory response by these cells [80]. In a macrophage-specific knockout 
mouse SIRT1 attenuates NF-κB mediated gene transcription thus predisposing 
mice to the development of insulin resistance and metabolic disorders [80]. The 
activity and expression of SIRT1 are also under control of systemic inflammation 
[79]. It has been shown that interferon gamma (IFNγ), represses the transcription 
of SIRT1, thereby disrupting metabolism and energy expenditure [81].  
1.6.1.6 SIRT1 and circadian rhythm 
Circadian rhythm is the biological 24 hour oscillation present in all living 
beings and work in part through chromatin modification and epigenetic control of 
gene expression [82]. Studies have shown that SIRT1 interacts with CLOCK-
BMAL1 (circadian locomotor output cycles kaput-aryl hydrocarbon receptor 
nuclear translocator-like, dimer transcription factor) to directly regulate the 
amplitude and duration of circadian clock controlled gene expression through 
deacetylation of PER2 (perdio carcadian protein homolog 2) and/or BMAL1 [83]. 
More over circadian regulation of SIRT1 activity is regulated by the cellular NAD 
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levels [84]. Phosphorylation of SIRT1 by DYRK1A (dual specificity tyrosine-
phosphorylation-regulated kinase 1A), an essential clock component activates its 
NAD dependent deacetylases activity in response to various environmental 
stresses [85-87]. These studies show a feedback loop involving CLOCK-BMAL1, 
Nampt, NAD and SIRT1, providing an important connection between 
physiological rhythm and cellular metabolism [85-87].  
1.6.1.7 SIRT1 regulates insulin sensitivity 
SIRT1 has been shown to directly regulate pancreatic insulin secretion 
thus improving systemic insulin sensitivity [45]. In skeletal muscle SIRT1 has 
been shown to stimulate mitochondrial fatty acid oxidation through PGC-1α 
thereby promoting insulin sensitivity [88, 89]. Moreover, SIRT1 improves 
systemic insulin sensitivity through interaction with AMP-activated protein kinase 
(AMPK) increasing fatty acid oxidation and mitochondrial biogenesis [90]. SIRT1 
directly regulates the secretion of adiponectin from adipocytes through 
deacetylation of FOXO1, improving insulin sensitivity in the liver and muscle 
tissues [91-94]. SIRT1 also represses the expression of PTP1B (protein-tyrosine 
phosphatase 1B) which is a negative regulator of insulin signaling, thereby 
improving insulin sensitivity under insulin-resistant conditions [95]. SIRT1 interact 
with insulin receptor substrates, IRS-1 and IRS-2 modulating insulin signaling 
[96]. Genetic deletion of SIRT1 in adipose tissues, myeloid cells and liver or 
systemic loss of a single copy of the SIRT1 gene has been found to cause the 
development of insulin resistance and signs of metabolic syndrome [97]. 
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Activation of SIRT1 by its activators such as the resveratrol and SRT1720 in 
animals protected against high-fat-induced obesity and insulin resistance [49-51].  
1.6.1.8 SIRT1 in endothelial cells and atherosclerosis 
SIRT1 is prominently expressed in ECs of growing blood vessel sprouts 
[98]. Loss of endothelial SIRT1 activity impaired the ability of ECs to form new 
vessels in response to ischemic stress [98]. Inactivations of SIRT1 impaired 
endothelial migration and sprout elongation and caused defects in vessel 
navigation, whereas overexpression of SIRT1 augmented such process [98]. In 
the vasculature of rodent models SIRT1 mediates vasodilatation via eNOS-
derived nitric oxide (NO) and scavenging reactive oxygen species (ROS) [99]. In 
the ECs SIRT1 plays an anti-inflammatory function by downregulating the 
expression of various pro-inflammatory genes (P-Selectin, ICAM-1 and VCAM-1) 
through the NF-κB signaling pathway [100]. SIR T1 in macrophages suppresses 
the expression of Lox-1 which is a scavenger receptor for oxidized low-density 
lipoproteins (oxLDL), preventing macrophage foam cell formation in 
atherosclerosis [101]. Also, SIRT1 has been shown to regulate the activity of 
Liver X-receptor (LXR), promoting ABCA1-driven reverse cholesterol transport in 
plaque macrophages [101]. SIRT1 exerts antithrombotic properties by 
suppresseing the expression of endothelial tissue factor (coagulation factor III) 
[102, 103]. SIRT1 deacetylase p53 in ECs preventing its activation and causing 
protection against vascular senescence in hyperglycemia [104, 105]. 
Overexpression of SIRT1 diminishes atherogenesis in mice and improves 
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vascular function [105]. Deletion of one SIRT1 allele increased atherosclerosis in 
hypercholesterolemic mice [101].  
1.7 FOXO1 
Some of the SIRTs activities are carried out through deacetylation of the 
FOXOs, i.e, forkhead family ‘O’ group of transcription factors [106]. Among the 
FOXO family, FOXO1 is best characterized and plays important roles in oxidative 
stress resistance, cell survival and cell death [107]. FOXO1 has a highly 
conserved DNA binding domain subjected to posttranslational modifications such 
as acetylation, phosphorylation and ubiquitination [108]. Such modifications can 
either increase or decrease the transcriptional activity of FOXO1 [108]. FOXO1 
acetylation by HAT such as p300 causes attenuation of its DNA binding ability 
and facilitates its phosphorylation by Akt, which leads to its export from the 
nucleus; whereas deacetylation increases FOXO1’s nuclear retention and 
transcriptional activity [106-108]. During oxidative stress FOXO1 is known to 
increase the expression of antioxidant genes (manganese superoxide dismutase, 
catalase) and thus promotes the scavenging of reactive oxygen species 
preventing DNA damages [109-112].  FOXO1 has important roles in systemic 
homeostasis. In mice, loss of FOXO1 is embryonically lethal [113]. FOXO1 also 
plays a role in regulating cardiac glucose and fatty acid (FA) metabolism [114]. 
FOXO1 upregulates gluconeogenesis by increasing hepatic glucose-6-
phosphatase and phosphoenolpyruvate carboxykinase [115]. In skeletal muscle 
and in HepG2 cells, FOXO1 increase pyruvate dehydrogenase kinase (PDK4) 
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expression thereby regulating glucose oxidation [116]. In chronic hyperglycemia, 
advanced glycated end products and their receptor activation cause modification 
of FOXO1 which enhance its transcriptional function independent of the 
phosphorylation state [117]. In diabetes, there is a decreased check on FOXO1 
activity by the insulin signaling pathway [118]. Under conditions of 
hypoxia/ischemia, transcription factors like hypoxia inducible factor (HIF-1α) are 
shown to interact with FOXO1 and enhance their transcriptional function [119]. In 
the liver, following FOX1 activation, important enzymes of gluconeogenesis like 
glucose-6-phosphatase, fructose-1,6-biphosphatase and phosphoenolpyruvate 
carboxykinase are increased [120]. FoxO1 is also known to enhance lipogenesis 
and lipid induced steatosis in liver [120]. In beta cells FOXO1 inhibit pancreatic 
and duodenal homeobox factor 1 (Pdx1) causing damage of beta cell function 
[121].  Due to their ability to promote cell cycle arrest by activation of p27kip1 (a 
G1 cyclin inhibitor) and c-myc (transcription factor), FOXO1 also have a tumor 
suppressive role [122]. Through the activation of pro-apoptotic proteins like Bim 
and caspases, they are known to increase tumor cell death [122]. Another 
important role of FOXO1 in inflammation and sepsis has been explored through 
their ability to co-ordinate with TLR4 (Toll-like receptor 4) and NF-κB [123].  
1.8 SIRT1 regulation by miRNAs 
miRNAs are small, non-protein coding RNAs, approximately 19-24 
nucleotides in length and highly conserved among species [124]. They regulate 
gene expression at the post transcriptional level through interaction with their 
target mRNA 3' untranslated region (UTR) [125]. miRNAs have significant effects 
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on the regulation of gene expression. The transcription of the miRNA occurs 
through RNA polymerase II [124-126]. The processing to precursor miRNAs 
(hairpin shaped, 70-100 nucleotides) in the nucleus is mediated by RNAse III, 
Dorsha and DGCR8. Following synthesis, they are exported to the cytoplasm by 
exportin 5 [126]. In the cytoplasm, they are further processed by Dicer into the 
functionally active mature miRNA. miRNA binds to the specific mRNA targets 
and causing degradation of specific mRNA or translational repression [124-126]. 
Several investigators have demonstrated importance of miRNA in diverse cellular 
processes [124-131]. miRNAs also play important roles in controlling histone 
modification. A significant number of miRNA coding regions are located in the 
intron of the protein coding gene and are usually co-regulated with their host 
genes [124-126].  
Epigenetic mechanisms play a fundamental role in the regulation of 
miRNAs [124-131]. In mammals, it is estimated that over one third of genes are 
regulated by miRNAs and on average one miRNA may regulate 100-200 different 
target genes, and a single gene may have several targets sites for various 
miRNA [124-126]. miRNAs are important players in a variety of cellular 
processes [128-137]. We have recently identified alterations of several miRNAs 
in diabetes [133-137].  
Sixteen miRNAs have been found to regulate SIRT1 [138]. These miRNAs 
regulate SIRT1 in brain, liver, pancreas, cardiac metabolism and tumorigenesis 
in various disease and normal conditions [138]. With respect to this project, we 
have identified by array studies significant upregulation of miRNA195 (a SIRT1 
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targeting miRNA) in the ECs exposed to glucose and in the retinal tissue in 
diabetes.    
1.9 Similarities of diabetic complications with aging 
A large number of structural and functional changes seen in diabetic 
complications are also found in normal cellular aging [139-158]. Cellular aging 
process or senescence is a phenomenon where cells demonstrate a reduced 
ability to multiply. It is characterized by reduced ability to respond to stress, 
increased susceptibility to diseases or infection, increased secretion of pro-
inflammatory cytokines, chemokines, growth factors, ECM proteins and 
increased homeostatic imbalance [139-158]. The biological basis of aging is still 
unknown however increased oxidative stress and DNA damage are known to 
induce senescence in cells [139-158].  
It is proposed that aging and longevity are determined by a complex 
mixture of environmental and genetic factors [139-158]. Researchers have 
demonstrated that selected alterations in specific genes can extend lifespan in 
model organisms and laboratory settings [49-51, 159, 160]. Increased DNA 
repair and telomerase activity, reduced oxidative damage and cell apoptosis can 
extend life span [139-158]. DNA damage is thought to be a common cause of 
aging [142, 150-158]. DNA damage caused by extrinsic factors such as, 
radiation, chemical or viral infection can prevent cell division or cause apoptosis 
in cells [142, 150-158]. It can often affect the stem cell pools hampering 
regeneration. However intrinsic causes such as ROS/RNS (reactive oxygen 
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species/reactive nitrogen species) are considered as one of the major drivers of 
DNA damage and aging [139-158]. 
Three metabolic pathways have been identified which influence the rate of 
aging: caloric restriction, the activity levels of the electron transport chain in the 
mitochondria and the insulin/IGF-1-like signaling pathway [161]. It may be 
possible that these three pathways affect aging separately as simultaneously 
targeting those leads to additive increases in lifespan [161]. The SIRT family of 
genes has been shown to have a significant effect on the lifespan of several 
species [32-34, 40]. In addition, diet has been shown to substantially affect 
lifespan in many animals including prevention or delay of many age-related 
diseases. In several model species caloric restriction has been found to lead to 
longer lifespans mediated by the nutrient-sensing function of the mTOR 
(mammalian target of rapamycin) pathway [140, 159-161]. This is thought to 
prevent spikes of glucose concentration in the blood, leading to improved insulin 
signaling [161]. Evidence in both animals and humans suggests that resveratrol, 
a known SIRT activator may be a caloric restriction mimetic [49-51, 161]. As 
more genetic connections to aging are being discovered, it is increasingly being 
considered similar to other genetically influenced conditions and potentially 
treatable. Similar to aging in diabetes, glucose induced oxidative damage is a 
key mediator of cellular damage. Such oxidative damage causes activation of 
several metabolic pathways ultimately converging on the nucleus. We and others 
have shown oxidative stress induced DNA damage in diabetes [11-13]. 
Ultimately such process causes aberrant expressions of cytokines, growth 
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factors, ECM proteins and structurally manifesting as changes such as cell loss, 
vascular sclerosis etc [11-13, 17-21, 24, 25, 28-31]. Hence tissue damage in both 
aging and diabetes may in part be mediated by similar mechanisms. 
1.10 Rationale 
As discussed above, changes in ECs and organs in diabetes such as 
increased oxidative stress, increased AGE, DNA damage, ECM protein 
production, cognitive decline, atherosclerosis, small vessel sclerosis are also 
observed in normal aging. Hence it is possible that high glucose in diabetes 
actually accelerates the aging process in cells and tissues. The mechanism of 
such process was investigated in this research. 
1.11 Hypothesis 
Diabetes, through oxidative damage, causes alteration of specific nuclear 
enzymes leading to an accelerated aging process. Such changes lead to 
alteration of vasoactive molecules and ECM proteins and causes development of 
chronic complications. 
1.12 Specific aims 
1. Aim1-to investigate accelerated aging in endothelial cells and in tissues in 
response to hyperglycemia and examine the role of SIRTs in such process 
2. Aim 2- to investigate SIRT1 regulation by microRNA 195 in diabetic 
animals 
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3. Aim 3-to investigate the effect of SIRT1 overexpression in the organ 
damage in diabetic animals  
Aim 1 was investigated in chapter 2. Aim 2 was investigated in chapter 3. Aim 3 
was investigated in chapter 4. 
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Chapter 2  
 
2 High glucose induced alteration of SIRTS in 
endothelial cells causes rapid aging in a p300 and 
FOXO regulated pathwaya 
Rokhsana Mortuza, Sali Chen, Biao Feng, Subhrojit Sen and Subrata 
Chakrabarti. Department of Pathology, Schulich School of Medicine & Dentistry,  
Western University,  London ON Canada. 
In this study our aim was to investigate accelerated aging in endothelial 
cells and in tissues in response to hyperglycemia and examine the role of SIRTs 
in such process. We examined 3 different ECs of various origins as well as 
kidney and retinal tissues of type 1 diabetic mice for this investigation. We also 
looked at the possible mechanism behind such glucose-induced rapid aging 
process. 
 
aA version of this chapter have been published: Mortuza R, Chen S, Feng B, 
Sen S, Chakrabarti S. High glucose induced alteration of SIRTs in endothelial 
cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One. 
2013;8(1):e54514. doi: 10.1371/journal.pone.0054514. As per the journal policy, 
authors retain ownership of the copyright for their content. No permission is 
required from the publishers. 
39 
 
2.1 Introduction 
Diabetes and its complications account for significant morbidity and 
mortality throughout the world [1-3]. The major factor in the development of 
chronic diabetic complications is vascular EC dysfunction [4]. The prevailing 
mechanism leading to EC dysfunction is an increase in reactive oxygen species 
(ROS) formation [5]. In response to high ambient glucose levels and subsequent 
oxidative stress, ECs elaborate large amount of vasoactive factors, growth 
factors and cytokines [6, 7]. Such factors lead to increased production of 
extracellular matrix (ECM) proteins causing structural alterations [6-8]. 
Interestingly, several such changes seen at the cellular and tissue level in 
diabetes are similar to the changes seen in normal aging process [9-13].  
Oxidative stress causes DNA damage and alters transcriptional machinery 
both in aging and in diabetes [4, 6, 14, 15]. We have previously shown that 
glucose induced oxidative stress causes histone acetylation by p300, which 
regulates several transcripts in diabetes [6, 16]. p300, a transcriptional 
coactivator with an intrinsic histone acetyltransferase (HAT) activity, regulates 
numerous transcription factors [6, 16, 17]. Acetylation by p300 and other HATs 
are balanced by histone deacetylases (HDACs).  
Silent information regulator 2 proteins or sirtuins (SIRTs) belong to Class 
III HDACs and regulates epigenetic gene silencing and suppress recombination 
of rDNA [18-20]. In mammals, SIRTs have a range of molecular functions and 
have emerged as important proteins in aging and metabolic regulations [18, 21]. 
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SIRTs represent a small gene family with seven members designated as SIRT1-
7, known to be modulated by oxidative stress [22].  
Some of the SIRTs activity is carried out through deacetylation of the 
FOXOs, forkhead family ‘O’ group of transcription factors [23-25]. Among the 
FOXO family, FOXO1 is best characterized and plays important roles in cell 
survival, oxidative stress resistance and cell death [26-29]. FOXO1 has a highly 
conserved DNA binding domain subjected to posttranslational modifications such 
as phosphorylation, acetylation and ubiquitination. These modifications can either 
increase or decrease the transcriptional activity of FOXO1 [17]. FOXO1 
acetylation by HAT such as p300, leads to attenuation of its DNA binding ability 
and facilitates its phosphorylation by Akt, leading to its export from the nucleus; 
whereas deacetylation increases FOXO1’s transcriptional activity [17, 24].  
 The purpose of this study was to investigate whether high glucose causes 
accelerated aging process in ECs through alteration of SIRTs. We further 
investigated whether the effects of SIRTs are mediated through FOXO1 and if 
such process is regulated by histone acetylase p300. We carried out these 
studies in various ECs as well as in the diabetic animals. 
2.2 Materials and methods 
2.2.1 Cell culture 
  Dermal-derived human microvascular EC (HMEC) was obtained from 
Lonza, Inc. (Walkersville, MD) and grown in EC basal medium 2 (EBM-2, 
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complete). Human umbilical vein ECs (HUVECs) were obtained from Lonza and 
cultured in EC growth medium (EBM complete, Walkersville, MD). Bovine retinal 
microvascular ECs (BRECs) were obtained from VEC Technologies (Rensselaer, 
NY) and grown in a defined EC growth medium (MCDB-131 complete). We have 
previously described the culture conditions of these three cells [30, 31]. No 
insulin was present in any media.  
For the long term continuous exposure to glucose, ECs were cultured in 
12 well plates (Corning, Acton, MA) and treated with 5mM glucose (NG) or 25mM 
glucose (HG, D-glucose) or osmotic control (OSM, 25 mM L-glucose). Upon 
confluence cells were propagated & maintained in the same treatment condition 
until they stopped proliferating completely. During each passage subculture cells 
from each treatment group were stained for SA β-gal and collected for RNA 
analysis. Cell lysates were collected with RIPA (Millipore, Billerica, MA) buffer 
with protease inhibitor (Roche, Laval, Canada) for ROS and MnSOD analysis. 
Total protein concentrations were measured by BCA protein assay kit (Pierce, 
Rockford, IL). Cells were monitored daily and images taken for morpholocigal 
and growth analysis. All experiments were conducted with 6-10 biological 
replicates. 
To test the effect of SIRT1 activation on accelerated aging in diabetes, 
cells were treated with 10 µM resveratrol (Sigma, Oakville, ON, Canada) 
dissolved in ethanol or 25 µM BML278 (Enzo, Farmingdale, NY) in DMSO for 72 
hr in HG following subculture in HMEC P1 (P1 = passage 1). To investigate the 
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effect of FOXO1 inhibition, cells were treated with 0.1 µM FOXO1 inhibitor 
AS1842856 (Millipore, Billerica, MA) in DMSO similarly.  
2.2.2 Animal experiments 
Male C57BL/6 mice (20-25g), were obtained (Charles River, Wilmington, 
MA) and diabetes was induced by a single intraperitoneal injection of 
streptozotocin (STZ) (65 mg/kg, in citrate buffer, pH 5.6). Age- and sex-matched 
mice were used as controls and given equal volumes of citrate buffer [32]. db/db 
(Leprdb, DBA/J) mice (8 weeks, Jackson Laboratory, CA) were used as type 2 
model of Diabetes [32]. The animals were monitored daily as described by us 
previously [32]. The animals were killed at 2 & 4 months following the 
development of diabetes (n = 10/group).  Retinal and renal cortical tissues were 
dissected out and snap frozen in liquid nitrogen. All tissues were stored at −80°C 
until further analysis. Urinary albumin (Exocell, Philadelphia, PA) and serum 
creatinine (Arbor assays, Ann Arbor, MI) were measured as per the instructions.  
2.2.3 Ethics statement 
Animal experiments were performed in accordance with regulations 
specified by the Canadian Council of Animal Care. The investigation was in 
compliance with the Guide for the Care and Use of Laboratory Animals (NIH 
publ. no. 85-23, revised 1996). All protocols were approved by the University of 
Western Ontario Animal Care and Veterinary Service. 
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2.2.4 SA β-gal staining of cells and frozen tissue sections 
Cells from each passage or tissue slides were fixed and stained with SA 
β-gal staining according to the manufacturer’s instructions (abcam, Cambridge, 
MA). Tissue slides were counterstained with H&E for orientation purpose. 
2.2.5 Phase contrast microscopy and morphometrical analysis 
Images of SA β-gal stained cells were photographed with phase contrast 
inverted microscope (Meiji Techno, TC5400, Santa Clara, CA) with 20X objective 
and SPOT Basic software. Morphometrical analysis of the images was done by 
ImageJ software (NIH, Bethesda, MD). Images (10 per sample) of the tissue 
slides were recorded by an Olympus BX51 microscope (Olympus, Center Valley, 
PA) with Northern Eclipse software (Empix Inc, Cheektowaga, NY). 
2.2.6 mRNA extraction and cDNA synthesis 
RNA extraction and cDNA synthesis from cells and tissues samples has 
been described by us previously [30].  RNA concentration was assessed on a 
spectrophotometer (Pharmacia Gene Quant, GE, Mississauga, ON, Canada). 
First-strand cDNA was made by using High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Carlsbad, CA, USA) as per the 
manufacturer instruction. 
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2.2.7 mRNA analysis with quantitative Real Time RT-PCR 
Real-time RT-PCR was performed by LightCycler™ (Roche Diagnostics, 
Laval, Canada) to quantify the mRNA expression of SIRT1, SIRT2, SIRT3, 
SIRT4, SIRT5, SIRT6, SIRT7, TERT (telomerase reverse transcriptase)  and 
p300  using the Qiagen One Step RT-PCR kit (SYBR Green I detection platform). 
All primers were either ordered or custom made from Sigma (Table 2.1). The 
data were normalized to housekeeping gene β-actin/18s mRNA to account for 
differences in reverse transcription efficiencies and the amount of template in the 
reaction mixtures. The details of the method have been described by us 
previously [30]. 
Table 2.1 The primers sequences for Real Time RT-PCR. 
Name of Primer Sequence (5’ to 3’) 
 
TERT CGTGGTTTCTGTGTGGTGTC 
CCTTGTCGCCTGAGGAGTAG 
FOXO1 AAGAGCGTGCCCTACTTCAA 
CTGTTGTTGTCCATGGATGC 
SIRT3  CATGAGCTGCAGTGACTGGT 
GAGCTTGCCGTTCAACTAGG 
SIRT4 CAGCAAGTCCTCCTCTGGAC 
CCAGCCTACGAAGTTTCTCG 
SIRT6  AGGATGTCGGTGAATTACGC 
AAAGGTGGTGTCGAACTTGG 
SIRT2  GACTTTCGCTCTCCATCCAC 
GGAGTAGCCCCTTGTCCTTC 
SIRT5  CCAGATTGTCCCAAGTCGAT 
CTGAAGGTCGGAACACCACT 
SIRT7  AGGGAGAAGCGTTAGTGCTG 
GGAACGCAGGAGGTACAGAC 
SIRT1 GCAGATTAGTAGGCGGCTTG 
TCTGGCATGTCCCACTATCA 
P300 GGGACTAACCAATGGTGGTG 
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ATTGGGAGAAGTCAAGCCTG 
 
2.2.8 Nuclear fraction isolation 
Nuclear fractions were isolated from ECs and tissues as per the kit 
instruction (Active Motif, Carlsbad, CA). Protein concentrations in the samples 
were measured by BCA protein assay (Pierce, Rockford, IL).  
2.2.9 FOXO1 DNA binding activity measurement 
FOXO1 DNA binding ELISA was conducted on the collected nuclear 
fraction as per the manufacturer’s instruction (Active Motif, Carlsbad, CA). The 
plates were read at 450 nm using a plate reader (Multiskan, Thermo Fisher, 
Canada). 
2.2.10 ROS, MnSOD and LDH analysis 
Total ROS level in the EC lysates were measured as per the manufacturer 
instructions using a commercially available kit (Cell Biolabs Inc., San Diego, CA). 
The plates were read with a fluorescent plate reader (Biotek, Winooski, VT) at 
excitation 480 nm and emission 530 nm.  MnSOD ELISA was done on cell and 
tissue lysates as per the manufacturer instruction (abcam, Cambridge, MA).  The 
plates were read at 450 nm using a plate reader (Multiskan, Thermo Fisher, 
Canada). Total protein concentrations were measured by BCA protein assay kit 
(Pierce, Rockford, IL). Quantification of intracellular lactate dehydrogenase (LDH) 
in the cell lysates was used as an additional measure of cell growth. The assay 
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was conducted as per the manufacturer instruction (Caymen Chemical 
Company, Ann Arbor, MI). 
2.2.11 Telomerase activity 
 Telomerase activities of the samples were measured using a commercially 
available kit following instructions provided by the manufacturer (Allied Biotech 
Inc., Vallejo, CA). 
2.2.12 Western blot 
200µg of protein was used for the western blot analysis according to the 
standard protocol established at our lab [6] using p300, Ac-FOXO1 & β-actin 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). 
2.2.13 SIRT1 enzyme activity analysis 
Enzyme assay for SIRT1 activity was performed as per the manufacturer 
instructions (Sigma, Oakville, CA). The plates were read with a fluorescent 
spectrophotometer (Biotek, Winooski, VT) at excitation 340 nm and emission 430 
nm. 
2.2.14 SIRT1 gene silencing 
To silence SIRT1, transfection of small interfering RNA (siRNA) was 
performed using N-TER nanoparticle siRNA transfection system (Sigma, 
Oakville, Canada) according to the manufacture’s protocol. SIRT1 siRNA1 was 
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purchased from Dharmacon Inc. (Lafayette, CO) and SIRT1 siRNA2 was 
purchased from Santa Cruz Biotecnology (Santa Cruz, CA). Cells were incubated 
with or without glucose after transfection for 24 hr and sample collected for 
mRNA analysis. To test the effect of SIRT1 siRNA on resveratrol, the siRNA was 
added 48 hr post treatment with resveratrol in the cultured cells and samples 
collected 24 hr post transfection. Transfection efficiency was assessed by real-
time RT-PCR. 
2.2.15 P300 gene silencing 
            To silence the p300 expression in ECs, p300 siRNA1 (Silencer, Ambion, 
Austin, TX) and p300 siRNA2 (Santa Cruz Biotechnology, Santa Cruz, CA) was 
used with siPORT Lipid transfection reagent (Ambion, Carlbad, CA). The details 
of the transfection protocol has been described by us previously [6,16]. siRNA 
transfection efficiency was indirectly assessed by measuring p300 mRNA 
expression by real-time RT-PCR.  
2.2.16 Statistical analysis 
Data are expressed as mean ± SEM (n ≥ 6), normalized to controls. The 
statistical significance of the results was analyzed by one way or two way 
ANOVA followed by Tukey’s HSD post hoc correction and the two tailed 
Student’s t-test as appropriate (PASW Statistics 18, IBM, Canada). P value < 
0.05 was considered statistically significant. 
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2.3 Results 
2.3.1 High glucose accelerates aging process in the ECs. 
Suspecting that hyperglycemia accelerates aging, we first investigated 
whether glucose causes rapid aging process in the ECs as they are the primary 
target of diabetic vascular complications. We examined three different ECs of 
various origins, at various passages following treatment with high glucose and 
used morphological alteration & senescence associated β-gal positivity as two 
biomarkers of aging.  
We found aging changes in HMEC starts as early as passage 1, as seen 
from positive β-gal staining in HG treated cells compared to NG treated cells 
where it appeared in passage 4. By passage 5, all cells in HG showed such 
changes, whereas in NG it was present in only 1.5% cells (Figure 2.1A and B). 
Additionally, cell growth was slower in HG treated groups compared to the NG 
treated cells. By passage 5, the HG treated cells stopped proliferating 
completely, whereas the cells in NG continued to do so (Figure 2.1D-F). The 
morphology of the cells also changed as they got older. The older cells became 
larger and irregular in shape compared to the smaller spindle shaped young 
cells. This process was exaggerated in HG. The average cell size in HG was 
significantly larger than the controls (Figure 2.1C). 
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Figure 2.1 Aging signs in microvascular endothelial cells (HMEC) with HG start 
as early as passage 1. (A) SA-βgal staining showed increased β-gal positivity or 
senescent cells with HG treatment compared to the NG treated cells, with the 
increasing passage number. Arrow indicates β-gal positive (blue) cells. [Scale 
bar represent 100µm for all micrographs]. (B) Quantification of β-gal positivity 
(n=10 image per sample). Signs of cellular aging started to appear from passage 
1 in HG. (C) Morphometric cell area analysis showed significant increase in cell 
size with HG treatment. Cell growth was slow with HG treatment compared to 
controls as seen from (D) days needed to be confluent in HG (90%, at which 
stage cells were subcultured to next passage), (E) cell count in HG (attached 
cells per microscopic field at 20X objective, n = 10 image) and (F) reduced 
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intracellular LDH activity in HG. (NG = normal glucose, 5 mM; HG = high 
glucose, 25 mM D-glucose; OSM = osmotic control, 25 Mm L-glucose; P = 
passage number). [*p<0.05 compared to NGP1; ǂp<0.05, ǂǂp<0.01 compared to 
respective NG passages for HG cultured cells].  
We then examined retinal endothelial cells, a major target in diabetic 
retinopathy. We found similar changes. In HG, BREC showed increased β-gal 
positivity and slower growth (Figure 2.2A and D-F). Similar to HMEC, such aging 
started as early as passage 1 in HG treated cells whereas with NG it appeared at 
passage 4. At passage 8 complete growth arrest and 100% β-gal positivity was 
seen in HG compared to 35% positivity in NG treated cells (Figure 2.2B). 
Furthermore, morphologically such aging changes were associated with a large 
and irregular appearance (Figure 2.2C). 
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Figure 2.2 Accelerated aging and associated changes in retinal endothelial cells 
(BREC) with increasing passages with HG treatment. (A) SA-βgal staining 
showing increased β-gal positivity (A) with HG treatment. Arrow indicates β-gal 
positive cells. [Scale bar represent 100µm for all micrographs]. (B) Quantification 
of β-gal positivity. Aging signs appeared at passage 1 with HG. (C) Morphometric 
cell area analysis showed significant increase in cell size with HG treatment. Cell 
growth was slow with HG treatment compared to controls as seen from (D) days 
needed to be confluent (90%, at which stage cells were subcultured to next 
passage), (E) cell count (attached cells per microscopic field at 20X objective, n = 
10 image) and (F) reduced intracellular LDH activity. (NG = normal glucose, 5 
mM; HG = high glucose, 25 mM D-glucose; OSM = osmotic control, 25 mM L-
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glucose; P = passage number). [*p<0.05, **p<0.01 compared to NGP1; ǂp<0.05, 
ǂǂp<0.01 compared to respective NG passages for HG cultured cells].  
Interestingly, although HUVECs showed similar changes, such process 
was delayed. HUVECs were a better survivor in HG environment. They were 
able to grow up to 11 passages in HG (Figure 2.3A). They showed signs of aging 
with HG at passage 4 and with NG at passage 7. β-gal positivity reached 100% 
at passage 11 in HG compared to 60% in NG at the same passage (Figure 
2.3B). In addition, similar to other ECs, aging was associated with large and 
irregular shape of these cells along with slow growth, (Figure 2.3C and D-F). 
Such changes were not seen with 25mM L-glucose (osmotic control) in any of 
the cell types (Figure 2.1, Figure 2.2 and Figure 2.3). 
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Figure 2.3 Accelerated aging in large vessel endothelial cells (HUVEC) with HG 
is delayed. (A) SA-βgal staining showed increased β-gal positivity (blue cells as 
indicated by arrow) with HG treatment compared to NG and osmotic control 
groups. Aging signs appeared later with HG in HUVEC. [Scale bar represent 
100µm for all micrographs].  (B) Quantification of β-gal positivity shows increased 
percentage of aged cells in HG treated group. (C) Morphometric cell area 
analysis showed significant increase in cell size with HG treatment. Cell growth 
was slow with HG treatment compared to controls as seen from (D) days needed 
to be confluent in HG (90%, at which stage cells were subcultured to next 
passage), (E) cell count in HG (attached cells per microscopic field at 20X 
objective, n = 10 image) and reduced (F) intracellular LDH activity in HG. (NG = 
normal glucose, 5 mM; HG = high glucose, 25 mM D-glucose; OSM = osmotic 
control, 25 mM L-glucose; P = passage number). [*p<0.05, **p<0.01 compared to 
NGP1; ǂp<0.05, ǂǂp<0.01 compared to respective NG passages for HG cultured 
cells]. 
As reduction of TERT has been found in many models of cellular aging, 
we investigated possible alteration in TERT mRNA expression. We investigated 
them at an early stage, (P1) and at the end passage (P5 in HMEC, P8 in BREC 
and P11 in HUVEC). We noticed TERT mRNA was significantly reduced in all 
ECs with HG treatment along with accelerated aging (Figure 2.4A).   
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Figure 2.4 Increased oxidative stress and reduced TERT mRNA expression 
observed in endothelial cells with HG. (A) HMEC, BREC & HUVEC showed 
reduction of TERT (telomerase reverse transcriptase) mRNA in HG treated cells. 
mRNA levels are expressed as a ratio to 18s and normalized to NG P1. (B) Total 
ROS levels in HMEC, BREC & HUVEC showed significant increase with HG and 
aging.  MnSOD levels in all cells at end passages (P5 in HMEC, P8 in BREC and 
P11 in HUVEC) showed significant reduction with HG treatment (C). (NG = 5 
mM; HG = 25 mM glucose, P1 = passage 1). Data normalized to NG (P1) 
treatments of the respective ECs. [*p <0.05 compared to NGP1; ǂp<0.05 
compared to NGP5 for HMEC, NGP8 for BREC and NGP11 for HUVEC].  
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In order to see whether such accelerated aging is associated with 
oxidative stress, we measured total ROS level in the cell lysate from early and 
late passages between the treatment groups. As anticipated, we found with HG 
the ECs produced more ROS than with NG, depicting higher level of oxidative 
stress in hyperglycaemia, which augmented with the increased passage number 
or aging (Figure 2.4B).  
Disruption of the scavenging of ROS in the mitochondria in aging is well 
known [33]. Manganese superoxide dismutase (MnSOD) is the primary 
mitochondrial ROS scavenging enzyme. It converts superoxide to hydrogen 
peroxide which is eventually converted to water by catalases and other 
peroxidases [29, 33, 34]. Our investigation of MnSOD in the final passages of the 
ECs showed a significant reduction of the enzyme in the aged cells (Figure 
2.4C). 
2.3.2 High glucose exaggerates down regulation of SIRTs in aging.  
We then examined whether above changes are associated with alteration 
of SIRTs. We found mRNA expressions of all SIRT (1-7) genes were reduced 
with increasing passages, in all ECs (Figure 2.5A, Figure 2.6A & Figure 2.7A). 
Such reduction was faster and exaggerated in HG treated groups. There were 
25-50% reductions in SIRT mRNA expressions with HG from as early as 
passage 1 in HMECs, which increased to 50% at passage 5 (Figure 2.5A). 
Similar reductions were observed in the BRECs (Figure 2.6A). HUVECs 
however, exhibited smaller reduction (15-30%) in earlier passages (Figure 2.7A). 
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Nonetheless by passage 11, mRNA levels in HG in HUVEC were reduced to 
almost half of NG treated cells (Figure 2.7A). Reduction in SIRT1 enzyme 
activities found in the ECs in final passages with HG treatment, were in keeping 
with the reduced mRNA levels (Figure 2.5B, Figure 2.6B & Figure 2.7B). As 
SIRT1 is one of the most important isoforms of the SIRT family which is 
associated with aging [5, 18, 24, 34], we focused on SIRT1 for the subsequent 
experiments. We carried out the following experiments in HMECs, as they are 
the major target of diabetic complications. 
 
Figure 2.5 SIRT (1-7) mRNA reduction in HG in microvascular endothelial cells 
(HMECs) parallels the accelerated aging. (A) Quantitative Real Time RT-PCR of 
SIRTs in HMEC showed significant reduction in the SIRT mRNA levels in HG 
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treated cells. mRNA levels are expressed as a ratio to β-actin normalized to 
baseline controls, NG P0 ( P0 = before start of treatment). [*p<0.05 compared to 
NGP0; ǂp<0.05 compared to respective NG passages for HG cultured cells]. (B) 
SIRT1 enzyme activity was reduced in HG in these endothelial cells (P5, data 
normalized to NG). (NG = 5 mM; HG = 25 mM glucose; P = passage number). 
[*p<0.05 compared to NGP5]. 
 
Figure 2.6 SIRT 1-7 mRNA analysis with Quantitative Real Time RT-PCR at 
various passages in BREC showed significant reduction in HG treated cells.  (A) 
SIRT (1-7) mRNA expressions in BREC with increasing passages. mRNA levels 
are expressed as a ratio to β-actin and normalized to baseline controls, NG P0 
(before treatment began). [*p<0.05 compared to NGP0; ǂp<0.05 compared to 
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respective NG passage for HG cultured cells]. (B) SIRT1 enzyme activity was 
reduced in HG in BREC (P8, data normalized to NG). (NG = 5 mM; HG = 25 mM 
glucose; P = passage number). [*p<0.05 compared to NGP8]. 
 
Figure 2.7 SIRT (1-7) mRNA reduction with increasing passage number is 
augmented with HG treatment in HUVECs. (A) SIRT (1-7) mRNA expressions 
are decreased in large vessel endothelial cells (HUVEC) with increasing 
passages and with HG it is escalated (analyzed by quantitative Real Time RT-
PCR). mRNA levels are expressed as a ratio to β-actin and normalized to 
baseline controls, NG P0 (before treatment began). [*p<0.05 compared to NGP0; 
ǂp<0.05 compared to respective NG passages for HG cultured cells]. (B) SIRT1 
enzyme activity was reduced in HG in HUVEC (P11, data normalized to NG). 
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[*p<0.05 compared to NGP11]. (NG = 5 mM; HG = 25 mM glucose, P = passage 
number).  
2.3.3 SIRT1 activators reduce glucose induced accelerated aging.  
As SIRT1 enzyme is significantly reduced in HG induced oxidative stress 
and aging, we investigated whether SIRT1 activators can rescue such process. 
Both resveratrol and BML278 significantly increased SIRT1 enzyme activity 
(Figure 2.8C) and reduced the sign of aging in HG as seen from reduced β-gal 
positivity (Figure 2.8A and B). As expected, SIRT1 activators reduced total ROS 
levels in the HG treated cells compared to the controls (Figure 2.8D).      
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Figure 2.8 Chemically induced activation of SIRT1 reduces oxidative stress in 
HG treated endothelial cells.  (A) SA β-gal staining of HMEC (P1) with resveratrol 
and BML278 treatment. β-gal positivity was reduced with SIRT1 activators in HG 
treated cells compared to controls. [Scale bar represent 100µm for all 
micrographs]. (B) Quantification of β-gal positivity. (C) SIRT1 activators 
significantly increased the enzyme’s activity and reduced (D) total ROS levels in 
HG. (E) FOXO1 DNA binding activity was reduced in the nuclear fractions of 
HMEC with SIRT1 activators along with increased (F) MnSOD levels. (G) 
Western blot analysis of acetylated FOXO1 shows HG induced increase in Ac-
FOXO1 level was corrected with SIRT1 activators. HG caused (H) nonsignificant 
change in TERT mRNA expression, however (I) telomerase activity was 
significantly reduced in the ECs and such reductions were prevented with SIRT1 
activators. mRNA levels are expressed as a ratio to β-actin. All data were 
normalized to NG. Osmotic controls with L-glucose had no effect. [*p<0.05, 
**p<0.01 compared to NG; ǂp<0.05 compared to HG].  
2.3.4 SIRT1’s action in ECs is mediated through FOXO1.  
To elucidate the mechanism of HG induced SIRT1 mediated oxidative 
stress and aging pathway, we looked into FOXO1, a major regulator of MnSOD 
and also a target of SIRT1 [17, 23, 24]. We observed FOXO1’s DNA binding 
activity in nuclear fractions of HMEC was reduced in HG and effectively rescued 
by the SIRT1 activators (Figure 2.8E). In parallel, investigation of MnSOD levels 
in these samples correlated with the reduced FOXO1 activity levels (Figure 
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2.8F). Finally Western blot analysis demonstrated, HG induced increased 
acetylated FOXO1 (Ac-FOXO1) levels were efficiently reduced with SIRT1 
activators (Figure 2.8G).  Together these results supported SIRT1 regulated 
MnSOD pathway in the ECs during HG induced rapid aging. 
We further examined TERT mRNA expressions and telomerase activity in 
the ECs with SIRT1 activators. In passage 1 although TERT mRNA was non-
significantly reduced, telomerase activity were reduced significantly in HG and 
such reductions were prevented by SIRT1 activators (Figure 2.8H and I).  
2.3.5 FOXO1 inhibitor or SIRT1 silencing in NG mimics the HG 
effects.  
To investigate the role of FOXO1 in such pathway further, we treated 
HMECs with a commercially available FOXO1 inhibitor (AS1842856) in NG. As 
expected FOXO1 inhibitor reduced FOXO1 DNA binding (data not presented) 
and subsequently reduced the MnSOD levels (Figure 2.9B). This led to an 
increase in ROS levels and induced early senescence as seen from increased β-
gal positivity (Figure 2.9A and C). In addition, FOXO1 inhibitor dampened the 
preventative effects of resveratrol on glucose-induced aging and oxidative stress, 
supporting the relationship of SIRT1 and FOXO1 (Figure 2.9A-C). Silencing of 
SIRT1 expression with siRNA (>50% reduction in mRNA expression, data not 
shown) in NG also showed similar effects and mimicked the HG effects (Figure 
2.9D and E). These findings confirmed our earlier findings and the specificity of 
SIRT1 and FOXO1 in the rapid aging pathway in these ECs. 
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Figure 2.9 SIRT1 knockdown or FOXO1 inhibition in NG induces signs of early 
aging mimicking the HG treatment. (A) Early senescence was induced with 
FOXO1 inhibitor (AS1842856) in NG, and the rescue of senescence with 
resveratrol in HG disappeared with FOXO1 inhibitor, as evidenced by SA-β gal 
stain (HMECP1). (B) In NG, AS1842856 reduced MnSOD and increased (C) 
ROS levels; it also hindered the preventative effect of resveratrol in HG regarding 
these parameters. [*p<0.05, **p<0.01 compared to NG; ǂp<0.05 compared to 
HG; ┼p<0.05 compared to HG+Resveratrol]. (D) SIRT1 knockdown with siRNA 
induced senescence in NG as seen using SA-β gal stain (HMECP1). (E) Such 
knockdown also increased ROS levels. siRNA1 and siRNA2 represent separate 
experiments using two different siRNAs. (F) Glucose induced increased SA β-gal 
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positivity was reduced with resveratrol. However SIRT1 siRNA transfection 
prevented such effect. (G) Analysis of SIRT1 mRNA level showed such effect of 
resveratrol is mediated through SIRT1. mRNA levels are expressed as a ratio to 
18s normalized to controls. (H) Glucose induced increased ROS production was 
prevented by resveratrol. However such preventative effects were partially lost 
with SIRT1 siRNA transfection. [*p<0.05, **p<0.01 compared to NG; ǂp<0.05 
compared to HG; ┼p<0.05 compared to HG+Res.+scramble].  (NG = 5 mM; HG 
= 25 mM glucose, P1 = passage 1).  [Scale bar represent 100µm for all 
micrographs].  
We then performed some additional experiments using SIRT1 siRNA in 
ECs following SIRT1 activation with resveratrol. We treated HMECs with SIRT1 
siRNA for 24 hrs following treatment with resveratrol for 48 hrs. We found the 
siRNA reversed the effect of resveratrol on mRNA expression, oxidative stress 
and aging (Figure 2.9F-H). This re-demonstrated the SIRT1 mediated aging in 
the ECs in hyperglycemia.  
2.3.6 SIRT1 and p300 have a balancing role on each other. 
 In order to explore the relationship of SIRT1 with other molecules in HG 
induced accelerated aging, we investigated possible association between SIRT1 
and p300. Since SIRT1 is a HDAC and actions of deacetylases are balanced by 
HATs, we examined p300, a well characterized HAT. To investigate such 
phenomenon, we knocked down SIRT1 in HMECs using siRNA and examined 
p300 mRNA expression and vice versa (Figure 2.10A and B).  We were able to 
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achieve more than 50% reduction of the specific mRNAs following the 
transfections (data not shown). SIRT1 silencing increased p300 mRNA 
expression in both NG and HG treated cells (Figure 2.10A). On the other hand, 
p300 silencing had no significant effect on basal SIRT1 mRNA level but reversed 
glucose induced reduction of SIRT1 expression indicating a possible regulatory 
role on each other (Figure 2.10B). To explore this relationship further we 
performed additional experiments investigating the downstream molecules 
(Figure 2.10C-F). We found p300 silencing in HG lead to a significant increase in 
FOXO1 DNA binding activity and subsequent MnSOD level compared to controls 
(Figure 2.10C and D). In addition, glucose induced increase of ROS and β- gal 
positivity were also reduced with p300 siRNA (Figure 2.10E-G). These findings 
together indicate that both SIRT1 and p300 regulate oxidative stress pathway in 
ECs through FOXO1.  
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Figure 2.10 SIRT1 and p300 regulate each other in microvascular endothelial 
cells.  (A) Quantitative Real Time RT-PCR analysis showed HG upregulated 
p300 mRNA and such effects are augmented by SIRT1 knockdown with siRNA. 
(B) HG induced downregulation of SIRT1 mRNA expression was corrected with 
p300 knockdown with siRNA. mRNA levels are expressed as ratio of 18s 
normalized to NG. (C) p300 siRNA reduced total ROS levels in HG by increasing 
(D) FOXO1’s DNA binding activity subsequently increasing (E) the MnSOD 
levels. (F, G) Microscopic photographs and quantitative analysis showed glucose 
induced increased SA β-gal positivity is effectively prevented by p300 siRNA. 
Data normalized to NG. (NG = 5 mM; HG = 25 mM D-glucose, OSM = 25 mM L-
glucose, P1 = passage1). [*p<0.05 and **p<0.01 compared to NG; ǂP<0.05 and 
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ǂǂp<0.01 compared to HG. Scale bar represent 100µm for all micrographs. 
siRNA1 and siRNA2 represent separate experiments using two different siRNAs]. 
2.3.7 Diabetes causes accelerated aging in kidney.  
Finally, in order to investigate if the findings in vitro is reflected in vivo, we 
used a well-established animal model, STZ induced C57BL/6 mice. Diabetic 
animals showed high blood glucose (23.43 ± 3.27 mmol/L vs. controls 7.3 ± 0.93 
mmol/L, p<0.001) and reduced body weight (22.50 ± 1.11 gm vs. controls 30.25 
± 2.04 gm, p<0.003). Urinary albumin concentration was increased (0.58 ± 0.07 
µg/mL vs. 0.21 ± 0.07 µg/mL in control, p<0.009) along with increased serum 
creatinine in the diabetic animals (0.52 ± 0.08 mg/dL vs. controls 0.18 ± 0.04 
mg/dL, p<0.02). Kidney tissues from diabetic mice showed increased β-gal 
positivity compared to the controls, supporting our in vitro findings (Figure 2.11A 
and B). This was further demonstrated as MnSOD levels, FOXO1 transcriptional 
activity, SIRT1 mRNA expression and enzyme activity were significantly reduced 
in kidneys of the diabetic animals along with an increased p300 protein levels in 
these tissues (Figure 2.11C-G).  
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Figure 2.11 Diabetes causes accelerated aging in mice kidney.  (A) SA β-gal 
staining of kidney tissue of STZ induced diabetic mice at 2 and 4 months 
showing increased positivity with uncontrolled diabetes. Arrow indicates β-gal 
positive cells. (B) Quantification of β-gal staining of the kidney tissue. Data 
presented as β-gal positivity/view (n = 10 image). (C) Shows reduction of 
MnSOD levels in kidney tissues of the diabetic animals following 2 and 4 months. 
(D) mRNA analysis confirmed downregulation of SIRT1 expressions in the kidney 
tissues of these animals. mRNA levels are expressed as a ratio to 18s 
normalized to controls.  (E) FOXO1 DNA binding and (G) SIRT1 enzyme 
activities are reduced in the kidney tissues in diabetes. (F) Western blot analysis 
showed increased p300 protein levels in the kidneys in diabetes. Data 
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normalized to controls. [*p<0.05 compared to control animals. Scale bar 
represents 100 µm for all micrographs].   
We further examined renal tissues from type 2 diabetic mice that were 
hyperglycemic and obese (data not shown). We found reduced MnSOD level 
following 2 and 4 months of diabetes in the kidney tissues of these animals 
(Figure 2.12A). mRNA analysis further showed reduced SIRT1 expression in 
these tissues (Figure 2.12B). In addition FOXO1 DNA binding activity was 
reduced in the kidneys of these mice (Figure 2.12C). 
 
Figure 2.12 Oxidative stress and associated changes are present in the kidneys 
and retinas of diabetic animals. (A) MnSOD levels were reduced in kidneys of 
db/db mice following 2 and 4 months of diabetes indicating increased oxidative 
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stress. (B, C) SIRT1 mRNA expression and FOXO1 activity in kidneys of db/db 
mice were reduced compared to controls. (D) SA β-gal staining of type 1 diabetic 
mice retina showed increased positivity in retinal blood vessels following 2 
months of diabetes. [Scale bar represent 50 µm for all micrographs]. Arrow 
indicates retinal blood vessels. (E) Such changes were associated with reduced 
MnSOD level in these tissues. (F, G) Shows reduction of SIRT1 mRNA 
expressions in retinal tissues of both type 1 and 2 diabetic mice. mRNA levels 
are expressed as a ratio to 18s  normalized to controls. [*p<0.05 compared to 
control animals].   
2.3.8 SIRT1 expression is reduced in retina with type 1 and type 2 
diabetes. 
Furthermore, we examined SIRT1 mRNA expression in retinas of the type 
1 and 2 diabetic animals. Retinal SIRT1 mRNA expressions were reduced in 
both models following 2 months of diabetes and the effects were pronounced 
after 4 months (Figure 2.12F and G). Further, SA β-gal staining of mice retina 
with type 1 diabetes showed increased positivity in the blood vessels following 2 
months of diabetes, along with reduced antioxidant levels in these tissues (Figure 
2.12D and E). 
2.4 Discussion 
 This study demonstrates that hyperglycemia accelerates aging both in 
vitro and in vivo. Although some studies have previously been performed [35] on 
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ECs investigating the effects of HG exposure for short term periods (24 to 72 hr), 
no study has yet been reported on chronic HG exposure of these cells, to 
simulate the process of chronic hyperglycemia in an in vitro setting. We 
simulated chronic hyperglycemia in the ECs with HG and propagated them in HG 
for weeks or even months until the cells stopped proliferation completely for more 
than 2 weeks. Such design allowed us to examine glucose induced accelerated 
aging process amongst ECs of different origins. We have seen signs of cellular 
senescence by SA β-gal positivity early in microvascular ECs and retinal ECs. 
However this process was slower in large vessel ECs. The differentiated ECs 
were more susceptible to hyperglycemia induced damage compared to HUVEC, 
which is more close to progenitor cells in terms of differentiation [36] and are a 
better survivor in hyperglycaemia. We have demonstrated that such process was 
associated with increased oxidative stress.  
 Molecular diversity in the genetic level in ECs of various origins has been 
studied before [37,38]. It has been shown that the gene expression profiles of 
ECs from large vessels are different from those of micro-vessels [39]. In keeping 
with these findings our study further demonstrated and elaborated some 
structural and functional significance of these type of changes. 
 We have shown an important role played by SIRTs in this study. Since the 
discovery of SIRTs, interests in these deacetylases have generated multiple lines 
of evidences indicating SIRTs as evolutionarily conserved regulators of lifespan 
[9, 18-21,40].  SIRTs regulate physiological response to metabolism and stress, 
the two key factors affecting the aging process. We found all SIRT1-7 mRNA 
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expressions were consistently reduced with the accelerated aging process in 
hyperglycemia. Although isolated SIRT alterations have been demonstrated in 
various studies [19, 20, 41-43], such comprehensive analysis of SIRTs have not 
been done. More interestingly, the level of SIRTs reduction paralleled that of β-
gal positivity and such changes were prevented by SIRT activators indicating an 
important relationship between SIRTs and aging. 
 SIRT1, the leading enzyme in the SIRT family is found both in the 
cytoplasm and nucleus and has been found to have protective roles in stress 
resistance and cell survival in various diseases [41, 44, 45]. This study showed 
glucose induced alteration of downstream mediators of SIRT1, such as FOXO1 
were corrected by SIRT1 activators further establishing the crucial role of SIRT1 
in this process.  The regulatory role of SIRT1 and p300 was further interesting. 
p300 and SIRT1 regulates each other as silencing one gene lead to increased 
expression of the other gene producing downstream affects. Other studies have 
shown, in a different model, p300 acetylates and activates PPAR-γ leading to its 
binding to SIRT1 promoter, thus decreasing SIRT1 expression [44]. Hence both 
direct and indirect relationship between these two molecules may exist in the 
ECs. 
We have previously shown that p300 regulates multiple transcription 
factors and proteins [6, 16]. Other studies have also shown acetylation of FOXO1 
by p300 facilitates its phosphorylation by Akt ultimately exporting it from the 
nucleus with chaperon 14-3-3 protein [24, 46]. In line with that, this study further 
showed HG induced upregulation of p300 leads to attenuation of FOXO1 DNA 
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binding activity in the ECs. This led to a reduction in MnSOD level, a known 
target gene of FOXO1 [27] and increased oxidative stress in the ECs. 
Furthermore, silencing p300 with siRNA corrected the MnSOD reduction and 
downstream changes in hyperglycemia, confirming such pathway.     
 On the other hand as FOXO1 deacetylation by SIRT1 is necessary for its 
retention in the nucleus [10, 29], we also found increased FOXO1 DNA binding 
with SIRT1 activators, which increased SIRT1 enzyme activity and reduced SA 
β-gal positivity.  Additionally, both FOXO1 inhibitor and SIRT1 siRNA was able to 
induce early senescence in NG, and mimicked the HG effect in the ECs. 
Together, these results indicate an important mechanistic pathway of oxidative 
stress and aging in HG, mediated through FOXO1 and regulated by SIRT1 and 
p300.  
 In keeping with the in vitro studies, STZ induced diabetic mice showed 
increased β-gal positivity in the kidneys following 2 & 4 months of uncontrolled 
diabetes. The retina showed increased signs of aging following 2 months of 
diabetes. This was accompanied by significantly reduced antioxidant levels in the 
tissues. In addition, SIRT1 mRNA was found to be significantly reduced in kidney 
and retina of both type 1 and type 2 diabetic mice.   
 In summary, this study showed chronic hyperglycemia accelerated aging 
process through a novel SIRT1 and p300 regulated pathway. We demonstrated 
HG induced reduction in SIRT1 lead to increased oxidative stress mediated 
through FOXO1 which was prevented by SIRT1 activation. We further 
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demonstrated p300 negatively regulates such pathway, as silencing p300 
mimicked resveratrol’s effect. Identification of such novel mechanisms will allow 
us to better understand the pathogenesis of diabetic complications as well as 
aging and eventually help to find potential therapeutic treatment. 
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Chapter 3  
 
3 miR-195 regulates SIRT1 mediated changes in 
diabetic retinopathyb 
Rokhsana Mortuza, Biao Feng and Subrata Chakrabarti.Department of 
Pathology, Schulich School of Medicine & Dentistry,  Western University,  London 
ON Canada. 
 
In this study our aim was to investigate SIRT1 regulation by miR-195 in 
diabetic animals. We investigated the role of miR-195 in glucose-induced SIRT1 
mediated changes in the ECs and retinas of type 1 diabetic rats. 
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3.1 Introduction 
Diabetic retinopathy is a growing problem worldwide with no specific 
medical treatment. In diabetic retinopathy, ECs of the retinal microvessels 
undergo a series of changes in response to hyperglycemia causing activation of 
several transcription factors [1-5]. Such processes lead to alteration of various 
gene expressions resulting in structural and functional damages [6]. Glucose-
induced oxidative stress mediated increased production of extracellular matrix 
(ECM) proteins such as fibronectin (FN) is a major characteristic feature of 
diabetic retinopathy. Glucose-induced increased FN synthesis in ECs and 
diabetes-induced augmented FN productions in the retina have been 
demonstrated previously [7-14]. It is of interest to know that FN upregulation is a 
common finding in endothelial and tissue aging [15-19].  
Researchers have found SIRT1, the longevity gene, play crucial role in 
regulating cell cycle, survival, metabolism and development across species since 
its identification [20-25]. We have demonstrated glucose-induced increased 
oxidative stress causes rapid aging in ECs and retinas in diabetes [26]. Such 
processes are mediated through alteration of Sirtuins (SIRTs), a family of NAD+ 
dependent class III histone deacetylases. Furthermore, transcriptional co-
activator p300 regulates such pathway by modifying both SIRT1 (leading enzyme 
in the SIRT family) and FOXO1 (forkhead O group of transcription factor) and 
altering the antioxidant levels in these ECs [26]. However, other post 
transcriptional ways of SIRT1 regulations also holds tremendous potential. 
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With the discovery of miRNAs, research on SIRT1 regulation has 
progressed and several miRNAs have been found to regulate SIRT1 in various 
tissues and disease conditions [27]. miRNAs are highly conserved small (19-24 
nucleotides), non-coding RNAs that regulate gene expression at the post 
transcriptional level, by binding with 3’UTRs (untranslated regions) of the specific 
mRNAs, causing their degradation or translational repression [27-29]. Over one 
third of genes are estimated to be regulated by miRNAs. miRNAs may play roles 
in many biological processes, including development of metabolic diseases such 
as diabetes [27-35].  
Although several researches have been conducted on miRNA mediated 
regulation of SIRT1 in various physiological and pathological conditions [25], no 
studies have been conducted on such regulation in diabetic retinopathy. In this 
study we investigated the role of a specific miRNA, miR-195 in regulating SIRT1 
in diabetic retinopathy.  miR-195 is upregulated in circulation in patients with 
hypertension, metabolic syndrome and glucose intolerance [36]. Similar 
increases were seen in kidney and liver tissues of diabetic animals [37, 38]. In 
cardiomyocytes, miR-195 was found to inhibit SIRT1 and thus promote palmitate-
induced apoptosis [39]. miR-195 deregulation has been associated with several 
other diseases, with upregulation in multiple cancers, hypertrophic 
cardiomyopathy and pre-eclampsia [40, 41]. In line with these research, our 
previous microarray analysis [42] showed miR-195 upregulation in glucose 
exposed ECs and in the retinas of diabetic rats. As SIRT1 is a possible target of 
miR-195 we explored this relationship further in diabetic retinopathy. 
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Since SIRT1 is a possible target of miR-195 (www.mirbase.org, 
www.microrna.org), we investigated whether miR-195 alteration occurs in 
diabetic retinopathy, and if such alterations causes EC aging in hyperglycemia. 
Microvascular ECs are the major target of glucose mediated damages in the 
retina, hence we examined human retinal and dermal microvascular ECs 
(HRECs and HMECs), to characterize glucose-induced miR-195 mediated 
regulation of SIRT1 and downstream cellular changes. We further expanded the 
study to investigate retinas of streptozotocin (STZ) induced type 1 diabetic 
animals [42, 43].   
 
3.2 Materials and methods 
3.2.1 Cell culture 
HRECs were obtained from Olaf Pharmaceuticals (Worchester, MA) and 
HMECs were obtained from Lonza, Inc. (Walkersville, MD). Cells were grown in 
EC basal medium 2 (EBM-2, Lonza, Walkersville, MD) and trypan blue dye 
exclusion test was used to examine cell viability as described [42-44]. The cells 
were passaged in 6 well plates (Corning, Acton, MA) and treated with normal 
glucose (NG, 5 mmol/l D-glucose) or high glucose (HG, 25 mmol/l D-glucose) or 
osmotic control (OSM, 25 mmol/l L-glucose) for 72 hours. Human embryonic 
kidney (HEK293A) cells were obtained from ATCC (Manassas, VA) and were 
used as previously described [42-44]. Reagents were obtained from Sigma 
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Chemicals (Sigma, Oakville, ON) unless specified otherwise. All experiments 
were conducted with 6-10 replicates. 
3.2.2 mRNA extraction and quantitative analysis   
TRIZOL™ (Invitrogen, Burlington, ON) was used to isolate RNA   [42-44]. 
Real Time RT-PCR was performed using High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Foster city, CA) , Qiagen One Step RT-
PCR kit with custom made SIRT1 and FN primers and LightCycler™ (Roche 
Diagnostics Canada, Quebec) as described [26, 43]. The data were normalized 
to 18sRNA [26, 43].  
3.2.3 miRNA extraction and analysis 
As described [42, 43], mirVana miRNA isolation kit (Ambion, Inc., Austin, 
TX) was used to extract miRNAs from cells and tissues. Real time RT-PCR was 
conducted with a reaction volume of 20 µL as described [42, 43]. 
3.2.4 miRNA mimic or antagomir transfection  
ECs were transfected with miRIDIAN microRNA-195 mimic or antagomir 
(20 nmol/l) (Dharmacon Inc., Chicago, IL) using Lipofectamine2000 (Invitrogen, 
Burlington, ON). Scrambled controls were used in parallel [42, 43].   
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3.2.5 Adenoviral forced-expression of SIRT1 and SIRT1 gene 
silencing 
SIRT1 adenovirus (devoid of 3’UTR) and null vector was obtained from 
ABM (Richmond, BC, Canada) and amplified in HEK293A cells. ECs were 
transduced with the adenovirus (with or without glucose) and following 72 hours 
of treatment samples collected.  To silence SIRT1, transfection of small 
interfering RNA (siRNA) was performed as described by us earlier [26]. 
 3.2.6 Luciferase Reporter Assay for Targeting SIRT1-3'UTR 
The luciferase vector including 3′UTR of SIRT1 (1080 bp) containing the 
SIRT1-miR-195 response elements (wt-Luc-SIRT1) and the mutant (mu-Luc-
SIRT1) were purchased from Norclone Biotech Laboratories (London, ON, 
Canada). Plasmid DNA (wt-Luc-SIRT1 or mu-Luc-SIRT1, β-galactosidase control 
vector) and miR-195 mimic or scrambled oligonucleotide were co-transfected in 
HRECs for 48 hours. Luciferase activity was measured using the Dual-Light 
Chemiluminescent Reporter Gene Assay System (Applied Biosystems, 
Burlington, ON) and SpectraMax M5 (Molecular Devices, Sunnyvale, CA) and 
normalized by measuring β-galactosidase activity.   
3.2.7 MnSOD, FN ELISA and SIRT1 enzyme activity assay 
MnSOD (manganese superoxide dismutase) and FN ELISA were 
performed using commercially available kits [26, 43]. As described earlier, [26] 
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SIRT1 enzyme activity was measured as per the manufacturer instructions 
(Sigma, Oakville, ON).  
3.2.8 Animal Experiments 
Animal experiments were conducted following guidelines specified by the 
Canadian Council of Animal Care. Protocols were approved by the Western 
University Animal Care and Veterinary Service. The investigations were in 
accordance with NIH publ. no. 85-23, revised 1996. 
Sprague-Dawley rats (~175g, 6 weeks, male) were obtained (Charles 
River, Wilmington, MA). Diabetes was induced by a single intraperitoneal 
injection of streptozotocin (STZ) (65 mg/kg, in citrate buffer, pH 5.6). Control 
animals received equal volume of citrate buffer.  Diabetes was determined as a 
blood glucose level >20 mmol/l on 3 successive days (Abbott Diabetes Care, 
Alameda, CA). The animals were fed on a standard diet with water ad libitum and 
monitored daily [42, 43]. A group of diabetic rats (n=7/group) received weekly 
intravitreal injections of 1.5 µg miR-195 mimic or antagomir in lipofectamine 
reagent in one eye. The other eye received scrambled control. They were 
sacrificed one week after the fourth injection. Retinal tissues were collected, snap 
frozen and were stored at −80°C until further analysis.  
To assess intravitreal miRNA penetration efficiency DY547 (red 
fluorescent dye) tagged miRNA scramble transfection control (Dharmacon Inc., 
Chicago, IL) was injected intravitreally and retinal tissues were collected from 
85 
 
sacrificed animals at 2 hr, 4hr, 8hr and 24hr following injection and snap frozen. 
DY547 tagged RNA has previously been shown to penetrate in the retina 
following intravitreal injection [45].  Slides from the same sections were 
counterstained with H&E for orientation. 
3.2.9 In situ Hybridization 
As described earlier [43, 46] 5' and 3' double DIG-labelled custom-made 
mercury LNA™ miRNA detection probes (Exiqon, Vedbaek, Denmark) were used 
to detect miR-195 expression using in situ hybridization(ISH) Kit (Biochain 
Institute, Hayward, CA) in retinal tissue sections. Scrambled probe and no-probe 
were used as controls.  
3.2.10 Immunohistochemistry 
IgG stainings were performed on frozen retinal sections using anti-rat IgG 
(ebioscience, Sandiego, CA) with hematoxylin counterstain as described [42, 43]. 
Quantification was done in a masked fashion using an arbitrary scale (0 = no 
extravascular stain of retina, 1 = mild extravascular stain,   2 = moderate 
extravascular stain,   3 = marked extravascular stain).  
3.2.11 SA β-GAL staining, phase contrast & fluorescent microscopy   
Cells or frozen retinal sections were stained with SA β-GAL staining kit 
(abcam, Cambridge, MA). Retinal slides were counterstained with H&E for 
orientation. From each specimen, positive (blue) cells were photographed with 
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phase contrast inverted microscope [26]. They were counted per 10 microscopic 
fields at 20X magnification and presented as % of total number of cells [26]. 
Tissue slides were quantified based on staining intensity at 60X magnification as 
described [47]. Fluorescent microscopies of frozen retinal sections were 
performed with TRITC filter at 20X magnification.   
3.2.12 Western Blot 
 Western blot analysis was conducted according to the standard protocol 
[10] using SIRT1 & β-Actin antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA). 
3.2.13 Statistical analysis  
Data are expressed as mean ± SEM, normalized to controls (n≥6). The 
statistical significances were analyzed by one or two way ANOVA followed by 
Tukey’s HSD post hoc correction and the two tailed Students t test as 
appropriate (PASW Statistics 18, IBM, Canada). A p value < 0.05 was 
considered statistically significant. 
 
3.3 Results 
In the initial screening of SIRT1 targeting microRNAs using our previously 
published array data of retinal tissues of normal and diabetic animals [42], we 
found miR-195 expression was increased almost 3 fold in the retinal tissues of 
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the diabetic animals (Table 3.1). Other SIRT1 targeting miRNAs such as miR-
34a, miR-138, miR-9 were reduced, and miR-217, miR-199a, miR-200a and miR-
132 expression levels were unchanged (Table 3.1). On the basis of our initial 
findings we further investigated the role of miR-195. 
Table 3.1 Fold changes of SIRT1 targeting miRNAs. 
miRNA Fold change (compared to control, p≤0.05) 
miR-195 2.8 
miR-34a 0.53 
miR-138 0.51 
miR-9 0.43 
miR-217 1.07 
miR-199a 1.04 
miR-200a 0.93 
miR-132 1.02 
 
3.3.1 High glucose causes upregulation of miR-195 and SIRT1 
downregulation in the ECs.  
Based on the hypothesis that glucose-induced SIRT1 downregulation is 
mediated by miR195, we investigated HRECs exposed to 5 (NG) and 25 (HG) 
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mmol/l D-glucose for 72 hrs. These concentrations are based on our previous 
dose dependent analysis of SIRT1 mRNA and protein expression [26].  We 
confirmed reduction of SIRT1 mRNA and enzyme activity following incubation 
with HG but not by 25 mmol/l L-glucose (osmotic control, OSM, Figure 3.1a and 
3.1c) in HRECs. We then extracted miRNA from these cells. Quantitative Real 
Time RT-PCR analysis of the ECs in HG confirmed significant upregulation of 
miR-195 compared to 5 mmol/l glucose. No effects were seen following 
incubation with 25 mmol/l of L-glucose (Figure 3.1b). 
 
Figure 3.1 miR-195 regulates SIRT1 in ECs in hyperglycemia. (a) SIRT1 mRNA 
and (b) miR-195 expressions in HRECs following exposure to HG and NG with 
miR-195 mimic and antagomir transfections. (c) SIRT1 enzyme activity and (d) 
protein levels with miR-195 mimic and antagomir transfections. (b) Efficiency of 
89 
 
miR-195 antagomir and mimic transfection in HRECs compared to scrambled 
controls. [HRECs= Human retinal microvascular endothelial cells, HG= 25 mmol/l 
glucose, NG= 5 mmol/l glucose, OSM= 25 mmol/l L-glucose. Scramble= 
scrambled miRNAs, 195= miR-195 mimics, 195(A)= miR-195 antagomirs, *= 
significantly different from NG, †= significantly different from HG. miRNA levels 
are expressed as a ratio to RNU6B (U6); mRNA levels are expressed as a ratio 
to 18s. All data are normalized to 5 mmol/l glucose. n=6] (e) Alignment of SIRT1-
3’UTR (and mutated SIRT1-3’UTR) sequence with mature miR-195 based on 
bioinformatics predictions (www.targetscan.org, www.microrna.org, 
www.mirbase.org). The 5' end of the mature miR-195 is the seed sequence and 
has perfect complementarity with six nucleotides of the 3'UTR of SIRT1. In the 
mutated sequence (small caps) such complementarity was lost. (f) Luciferase 
reporter assay in HRECs, showing dose dependent binding of SIRT1-3'UTR with 
miR-195. Mutated (mut) SIRT1-3'UTR abrogated the inhibitory effects of miR-
195. [Relative luciferase activities were expressed as luminescence units, 
normalized for β-galactosidase expression, *= significantly different from vector 
or mut. Vector= SIRT1-3’UTR luciferase plasmids+β-galactosidase plasmids, 
SIRT1 mut= mutated SIRT1-3’UTR luciferase plasmids+β-galactosidase 
plasmids. n=6]. (g) shows cellular MnSOD levels with miR-195 antagomir 
transfection in HG, n=6. 
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3.3.2 Glucose-induced SIRT1 reduction in the ECs is mediated by 
miR-195. 
We then proceeded to explore functional significance of such glucose-
induced miR-195 upregulation with respect to SIRT1 expression. To find a 
cause-effect relationship, we transfected cells in 25 mmol/l glucose with miR-195 
antagomir. Transfection efficiencies, assessed by measuring miR-195 expression 
showed substantial reduction in intracellular miR-195 expression compared to 
scrambled miRNA transfection (Figure 3.1b). Such reduction could be attributed 
by degradation of the miRNA following binding with antagomir [48]. Additionally 
irreversible binding of antagomirs with the miRNAs may further prevent 
amplification.  
Such transfection effectively rescued glucose-induced SIRT1 downregulation. No 
such effects were seen with scrambled miRNAs (Figure 3.1a, c). On the other 
hand, transfection of the ECs in 5 mmol/l glucose with miR-195 mimic 
downregulated SIRT1 mRNA production and enzyme activity mimicking the 
effects of 25 mmol/l glucose (Figure 3.1a-c). Furthermore, SIRT1 protein and 
enzyme analysis showed glucose-induced reduced SIRT1 enzyme activity in the 
ECs is prevented by miR-195 antagomir transfection (Figure 3.1c, d). On the 
other hand, transfection of HRECs in NG with miR-195 mimic caused effects 
similar to HG by reducing SIRT1 levels in these ECs (Figure 3.1a-d).  
In parallel, we conducted similar experiments in HMECs (to examine 
whether the changes are unique to HRECs or universal to other microvascular 
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ECs) which showed similar effects confirming the changes observed in HRECs 
(Figure 3.2a-d). 
 
Figure 3.2 miR-195 regulates glucose-induced SIRT1 mediated aging changes in 
HMECs. Human dermal microvascular endothelial cells (HMECs) showed 
glucose-induced (a) miR-195 upregulation (n=10) and (b) SIRT1 downregulation. 
(b-d) Transfection of HMECs with miR-195 antagomirs normalized HG induced 
downregulation of SIRT1 mRNA and enzyme activity; (c) shows efficiency of 
miR-195 antagomir and mimic transfection. n=6. (e) Senescence associated SA-
βGAL staining of HMECs showed increased positivity with 25 mmol/l glucose 
(HG) treatment compared to 5 mmol/l glucose (NG) and 25 mmol/l L-glucose 
(OSM). MiR-195 antagomir transfection successfully prevented such signs of 
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cellular aging. Such changes were not seen in cells transfected with scrambled 
miRNA. Arrow indicates positive cell (blue). (f) Quantitation of SA-βGAL 
positivity, n=10 image/treatment. (g) shows HG induced induced reduction of 
cellular MnSOD levels were normalized with miR-195 antagomir transfection, 
n=6. [Scramble= scrambled miRNAs, 195= miR-195 mimics, 195(A)= miR-195 
antagomirs, *= significantly different from NG, †= significantly different from HG. 
MiRNA levels are expressed as a ratio to RNU6B (U6); mRNA levels are 
expressed as a ratio to 18s. All data are normalized to 5 mmol/l glucose. 
MnSOD= manganese superoxide dismutase. Scale bar represent 100 µm for all 
micrographs. Inset = magnified image showing cytoplasmic SA-βGAL positivity.]  
3.3.3 miR-195 binds to 3’UTR of SIRT1 mRNA. 
To examine direct binding of miR-195 with 3'UTR of the SIRT1 mRNA, we 
did Luciferase assays in HRECs. We co-transfected miR-195 mimic with 
Luciferase reporter plasmids having cloned miR-195 binding sites for SIRT1-
3'UTR or mutated SIRT1-3'UTR. SIRT1-3'UTR luciferase activity was 
significantly repressed with such miR-195 overexpression, which was however 
not seen with mutated SIRT1-3'UTR (Figure 3.1e, f and Figure 3.3a). These 
results confirmed binding of miR-195 with 3'UTR of SIRT1 mRNA. 
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Figure 3.3 Plasmid map showing (a) site of SIRT1- 3’UTR (wt/mut) insertion in 
the vector (pMIR-Report-Luciferase plasmid) in regards to the luciferase assay. 
3.3.4 miR-195 antagomir prevents HG-induced reduction of SIRT1 
regulated antioxidant levels. 
To investigate glucose-induced downstream functional alterations of such 
miR-195 increase in ECs, we measured intracellular antioxidant levels. In 
previous studies we have established such SIRT1 mediated changes in the ECs 
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[26]. SIRT1 regulated antioxidant MnSOD analysis showed upregulation of this 
enzyme with miR-195 inhibition (Figure 3.1g). Likewise, HMECs showed similar 
effects of miR-195 inhibition in 25 mmol/l glucose (Figure 3.2g).  
3.3.5 miR-195 antagomir averts FN upregulation in ECs. 
Increased production of ECM protein FN is a characteristic feature of 
diabetic retinopathy [7-14]. Hence we examined FN mRNA and protein level in 
these ECs. miR-195 antagomir transfection (not scrambled controls) attenuated 
HG-induced increased FN mRNA and protein levels in the ECs (Figure 3.4a, b). 
Moreover, knockdown of SIRT1 with siRNA in NG showed glucose-like effect in 
which there was an increase in FN mRNA and protein levels confirming such 
regulation (Figure 3.4c and Figure 3.5a, b). Such effect was not seen with 
scrambled siRNA treatment (Figure 3.4c and Figure 3.5a, b). 
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Figure 3.4 SIRT1 forced-expression prevents glucose-induced FN upregulation in 
ECs. (a) FN mRNA and (b) FN protein levels in HRECs with miR-195 transfection 
in HG. (c) FN mRNA levels following SIRT1 knockdown with siRNA in NG in the 
ECs. (d) SIRT1 enzyme activity with adenoviral overexpression in the ECs 
confirming transfection efficiency at the functional level. (e) FN mRNA levels in 
HG with Ad-SIRT1 transfection. (f) FN mRNA levels in NG with miR-195 mimic 
and Ad-SIRT1 transfection. [HG= 25 mmol/l glucose, NG= 5 mmol/l glucose, 
195= miR-195 mimics, 195(A)= miR-195 antagomirs, *= significantly different 
from NG, †= significantly different from HG; mRNA levels are expressed as a 
ratio to 18s normalized to NG. HRECs= human retinal microvascular endothelial 
cells. All data normalized to controls. n=6] 
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Figure 3.5 SIRT1 knockdown in NG increases FN protein levels in HRECs. (a) 
SIRT1 knockdown efficiency with siRNA in NG shows significant reduction of 
SIRT1 mRNA levels in the ECs and such reduction caused an increase in (b) FN 
protein levels. Such increase is absent in scramble siRNA treated cells. (c, d) 
Shows effect of miR-195 antagomir treatment in HRECs in passage 3 has 
preventative effect against HG induced accelerated aging changes in these cells, 
n=10 image/treatment. (e) Shows MnSOD level in HREC passage 3 following 
miR-195 antagomir transfection. HG induced reduction of MnSOD level is 
efficiently increased with such treatment in these ECs. [Scramble = scrambled 
miRNAs. 195(A)= miR-195 antagomirs, HRECs = human retinal microvascular 
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endothelial cells. *= significantly different from NG, †= significantly different from 
HG. P3= passage 3, MnSOD= manganese superoxide dismutase. Data 
normalized to NG. Scale bar represent 100 µm for all micrographs. Inset = 
magnified image showing cytoplasmic SA-βGAL positivity. n=6]  
3.3.6 SIRT1 forced-expression prevents FN upregulation in ECs. 
 We further wanted to see if forced-expression of SIRT1 can prevent FN 
upregulation in ECs in hyperglycemia. We transfected HRECs with SIRT1 
adenovirus and analysed the cells with Real Time RT-PCR (data not presented). 
SIRT1 enzyme activity was increased following the transfection in HG treated 
ECs compared to empty vector controls (Figure 3.4d). Such increase activity 
normalized the HG induced FN upregulation in these cells (Figure 3.4e). In 
parallel, we conducted similar experiments in HMECs which were in line with the 
findings observed in HRECs (Figure 3.6a-d).  
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Figure 3.6 SIRT1 forced-expression showed preventative effect against glucose-
induced damage in HMECs. Transfection of miR-195 antagomir prevented 
glucose-induced upregulation of (a) FN mRNA and (b) protein levels in the 
HMECs. (c) Adenoviral forced-expression of SIRT1 in the ECs increased the 
enzyme’s activity both in NG (5 mmol/l glucose) and HG (25 mmol/l glucose) 
confirming transfection efficiency at the functional level. Such increase in activity 
were absent in null vector transfected ECs. Ad-SIRT1 transfected ECs showed 
(d) attenuated upregulation of HG induced FN mRNA levels and (e) reduced 
signs of aging with SA β-GAL stain. Arrow indicates positive cell (blue). (f) 
Quantitation of SA β-GAL positivity, n=10 image/treatment. [195(A)= miR-195 
antagomirs, *= significantly different from NG, †= significantly different from HG; 
mRNA levels are expressed as a ratio to 18s normalized to NG. HMECs= human 
dermal microvascular endothelial cells. All data normalized to controls. Scale bar 
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represent 100 µm for all micrographs. Inset = magnified image showing 
cytoplasmic SA β-GAL positivity. n=6] 
We further conducted an additional experiment to see if the effects of miR-195 
are reversible. We observed adenoviral overexpression of SIRT1 (plasmid 
lacking the binding site of miR-195), reverses the miR-195 mimic induced 
upregulation of FN mRNA levels in NG (Figure 3.4f). Such finding shows the 
detrimental effects of miR-195 is reversible, and confirms miR-195 mediated 
regulation of SIRT1 and downstream changes in these ECs.  
3.3.7 miR-195 is overexpressed in the retina in diabetes. 
We then moved to a well-established animal model to examine, if the 
mechanisms seen in ECs are indeed involved in the development of retinal 
microangiopathy. We used STZ- induced diabetic rats demonstrating 
hyperglycemia (serum glucose of diabetics 20.2±1.9 mmol/l vs controls 5.3±0.7 
mmol/l, p<0.001) and reduced body weight (diabetics 299.0±59.2 g vs controls 
460.8±13.2 g, p<0.001). Real Time RT-PCR analysis of retinal tissues of these 
animals following 1 month of uncontrolled diabetes showed significant 
upregulation of miR-195 (Figure 3.7a). It is of interest to note that, we have 
previously shown in this model, diabetes causes increased ECM protein and 
vasoactive factor expression at this time point [42, 43]. Such notion was further 
confirmed by using in situ hybridization and LNA probes. In the retinas of diabetic 
animals, miR-195 was overexpressed in the cells of inner and outer nuclear 
layers, ganglion cell layers and ECs of the microvessels (Figure 3.7b). 
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Figure 3.7 miR-195 is overexpressed in the retina in diabetes. (a) Rat retinal 
miR-195 expressions in control and diabetic animals. (b) LNA-ISH analysis of 
retinal tissues of control and diabetic animals. Blue chromogen shows miR-195 in 
the cells of the inner nuclear layers (thin arrow), outer nuclear layers (thick 
arrow), ganglion cell layers (arrowhead) and endothelial cells of the microvessels 
(arrow, inset). Diabetic rat retina stained with scrambled miRNA probes lacking 
such stain confirmed specificity of the miR-195 probe. Insets show enlarged view 
of the retinal capillaries. (Scale bar = 50 µm for all micrographs). [*= significantly 
different from control. miRNA levels are expressed as a ratio of RNU6B (U6) 
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normalized to control. ALK Phos was used as chromogen (blue) with no counter 
stain in LNA-ISH. n=7 eye/treatment] 
3.3.8 Diabetes induced SIRT1 downregulation in the retina and its 
downstream effects are mediated by miR-195. 
To establish the functional consequence of miR-195 upregulation in the 
retina, we investigated retinal SIRT1 mRNA and enzyme levels which is a target 
for miR-195. Diabetes-induced miR-195 upregulation was associated with SIRT1 
mRNA downregulation (Figure 3.8c). Simultaneously SIRT1 protein and enzyme 
level was also reduced in the retina in diabetic rats (Figure 3.8d, e). To find a 
cause-effect relationship, we performed intravitreal miR-195 antagomir injection. 
Penetration efficiency of such drug delivery was confirmed with DY547 tagged 
miRNA injection, which shows effective transfection of the miRNA in rat retinal 
layers and microvessels following 2 hours of the injection (Figure 3.8a). 
Intraretinal delivery efficiencies, assessed by measuring miR-195 expression in 
the retina, showed reduction in retinal miR-195 expression (Figure 3.8b). Such 
intravitreal miR-195 injection normalized diabetes-induced SIRT1 reduction in the 
retinas of the treated animals (Figure 3.8c-e). We further measured antioxidant 
level in the retinas. Diabetes-induced reduction of retinal MnSOD levels were 
prevented with miR-195 antagomir injection (Figure 3.8f). No such prevention 
was seen with injection of scrambled oligonucleotides or vehicles (Figure 3.8f). In 
addition, injection of miR-195 mimic in control animals caused effects similar to 
diabetes with reduced SIRT1 mRNA and MnSOD levels (Figure 3.8c, f). 
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Figure 3.8 miR-195 antagomir treatment can ameliorate diabetes induced 
reduction of antioxidant levels in retinal tissues. (a) Fluorescent microscopy 
images of rat retinas following intravitreal injection of DY547 tagged miRNA and 
vehicle demonstrating penetration. Arrows show various layers of rat retina. Inset 
shows enlarged view of retinal microvessels.  (Scale bar= 100 µm for both 
micrographs). (b) Retinal miR-195 expression following intravitreal injection of 
miR-195 antagomir to assess efficiency of intravitreal delivery. (c) SIRT1 mRNA 
levels in the rat retinas following intravitreal miR-195 antagomir treatments. (d) 
SIRT1 protein level and (e) enzyme activity following such injections. (f) Shows 
MnSOD levels in the retinal tissues of the control and diabetic animals following 
miR-195 mimic and antagomir injections. [*= significantly different from control 
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(Co), †= significantly different from diabetic (Di) or Di+Scramble. 195= miR-195 
mimics, 195(A)= miR-195 antagomirs. miRNA levels are expressed as a ratio of 
RNU6B (U6) normalized to control; mRNA levels are expressed as a ratio to 18s 
normalized to control. MnSOD= manganese superoxide dismutase. DY547= red 
fluorescent dye. n=7 eye/treatment] 
We further expanded the study to see the downstream effects of miR-195 
mediated increased oxidative stress and measured the level of FN protein in the 
rat retinal tissue. We observed diabetes-induced upregulated FN protein levels in 
the retina were reduced by intravitreal mir-195 antagomir injection. Retinal tissue 
with scrambled miRNA treated animals did not show such effects (Figure 3.9a). 
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Figure 3.9 miR-195 antagomir prevents diabetes-induced increased FN protein 
and vascular leakage in retina. (a) FN protein levels in rat retinal tissues with 
intravitreal miR-195 antagomir injections in the diabetic animals. (b) 
Immunohistochemical stains on the rat retinas following miR-195 antagomir 
treatment. Brown chromogen indicates IgG extravasation. (Hematotoxylin 
counterstain). Arrow shows diffuse staining in the retina of the diabetic animal. 
[195(A)= miR-195 antagomirs,  *= significantly different from control (Co), †= 
significantly different from diabetic (Di) or Di+Scramble;  Scale bar represent 50 
µm for all micrographs. Data normalized to controls. Inset = magnified images of 
retinal microvessels. n= 7 eye/treatment] 
We then investigated permeability changes and measured IgG 
extravasation from the retinal vasculature using an IgG immunostaining. We 
found diabetes-induced increased vascular permeability was reduced by the 
miR-195 antagomir injection (Figure 3.9b). No extravascular IgG was seen in the 
control animals (score= 0). Diabetic animals demonstrated a score of 2 to 3, 
indicating increased extravasated IgG. Scores of 0 to 1 were noted in eyes 
injected with the miR-195 antagomir, indicating prevention of diabetes-induced 
increased vascular permeability by such treatment. 
3.3.9 miR-195 antagomir prevents SIRT1 mediated EC senescence 
in hyperglycemia. 
As SIRT1 is an aging-associated molecule and we have previously shown 
that the changes in diabetes are comparable to accelerated aging [26], we 
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investigated additional downstream alterations of miR-195 increase and SIRT1 
downregulation in ECs and retina. We stained the cells with SA β-GAL (a 
lysosomal enzyme accumulated in senescent cell), an established marker for 
assessing cellular senescence [26, 47]. miR-195 antagomir transfection (not 
scrambled controls) prevented HG induced ECs aging, as evidenced by reduced 
β-GAL positivity (Figure 3.10a, b and Figure 3.2e, f). Furthermore, HRECs 
transfected with miR-195 mimic in NG caused cellular changes similar to HG 
(Figure 3.10a, b). On the contrary, adenoviral overexpression of SIRT1 in HG 
ameliorated such effects in the ECs (Figure 3.10a, b and Figure 3.6e, f).  
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Figure 3.10 miR-195 inhibition halts glucose-induced SIRT1 mediated cellular 
senescence in ECs. (a) Senescence associated SA β-GAL staining of HRECs in 
HG and NG following miR-195 mimic, antagomir and with Ad-SIRT1 transfection. 
Arrow indicates positive cell (blue). (b) Quantitation of SA β-GAL positivity, n=10 
image/treatment. [Scale bar represent 100 µm for all micrographs. Inset = 
magnified image showing cytoplasmic SA β-GAL positivity. HRECs = human 
retinal microvascular endothelial cells. HG= 25 mmol/l glucose, NG= 5 mmol/l 
glucose, OSM= 25 mmol/l L-glucose. *= significantly different from NG, †= 
significantly different from HG.] (c) SA β-GAL staining of rat retinal sections 
following intravitreal miR-195 antagomir treatment, n=10 image. Arrow shows 
retinal inner nuclear layers. No counterstain. [Inset = magnified images of retinal 
microvessels. Scale bar represent 50 µm for all micrographs. 195= miR-195 
mimics, 195(A)= miR-195 antagomirs. *= significantly different from control, †= 
significantly different from diabetic (Di) or Di+Scramble] 
We expanded the study and investigated miR-195 mediated cellular 
changes at a later passage [26]. miR-195 antagomir transfection in HRECs at 
passage 3 showed reduction of cellular senescence along with increased 
MnSOD level with such treatment (Figure 3.5c-e). In parallel, retinal tissues 
stained with SA-βGAL showed increased positivity in the diabetic animals. Such 
positivity was significantly reduced with intravitreal miR-195 antagomir treatment 
in the retina, especially in ECs of the microvessels (Figure 3.10c). Scrambled 
miRNA treated diabetic animals lacked such improvements (Figure 3.10c). 
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3.4 Discussion 
In this study we have shown a novel role of miR-195 in regulating 
hyperglycemia induced changes in microvessels in diabetic retinopathy. Using 
miR-195 antagomir transfection, we have demonstrated that diabetes-induced 
SIRT1 downregulation and subsequent functional consequences can be 
prevented by decreasing the availability of miR-195. We further verified the in 
vitro findings in vivo, by injecting miR-195 antagomir intravitreally in STZ induced 
type 1 diabetic rats, which showed such treatment prevented SIRT1 reduction in 
these tissues following 1 month of uncontrolled hyperglycemia, and normalized 
FN proteins levels in diabetes.  Such role of miR-195 regulated, SIRT1 mediated 
FN regulation and aging-like changes, in glucose-induced ECs and retina of 
diabetic animals have not been reported earlier. 
In diabetes, overproduction of superoxides by the mitochondrial electron 
transport chain in the ECs causes DNA damage, activating several transcription 
factors and altering multiple gene expressions [6, 9-11, 49]. We have 
demonstrated that glucose-induced SIRT1 mediated downregulation of MnSOD 
causes aging like changes in the ECs and retina in diabetes [26]. Such changes 
are also regulated by transcriptional coactivator and histone acetyl transferase 
p300 [26]. In this research, we have characterized another level of regulation of 
glucose-induced SIRT1 downregulation and its downstream effects through 
alteration of miR-195. 
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Several lines of evidence have recently been presented to demonstrate 
that miRNAs play a significant role in a large number of cellular processes [27-
34]. Adding to such data, we have previously showed miR-200b & miR-146a 
plays an important role in diabetic retinopathy through VEGF and FN modulation 
respectively [42, 43]. Here we described the role of miR-195 causing SIRT1 
downregulation in ECs, which also mediate aging-like changes, vascular 
permeability and FN upregulation in diabetes. We investigated the mechanisms 
at multiple levels of complexities. After the initial identification of miR-195 
upregulation in the human retinal capillary ECs, we used miR-195 antagomir and 
mimic to identify in vitro biological significance. We further observed similar 
changes in human dermal microvascular ECs. We have also showed similar 
alterations and functional significance of this mechanism in an established animal 
model of diabetic retinopathy. 
Several changes seen in chronic diabetic complications are similar to 
normal aging process [7-19].  However, such changes are accelerated in 
diabetes and we have demonstrated they are mediated by oxidative stress 
induced SIRT alterations [26]. Increased FN production has been demonstrated 
in aging [15-19]. Furthermore, augmented ECM protein such as FN production is 
a characteristic feature of diabetic retinopathy and is a result of EC dysfunction 
induced by hyperglycemia [7-14]. We and others have previously demonstrated 
glucose-induced increased FN synthesis in the ECs and in the retina in diabetes 
[7-14]. Such increased FN production can cause outside-in signaling and 
alteration of vasoactive factors [14, 44].  This is the first study to demonstrate 
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SIRT1 mediated FN regulations in diabetic retinopathy, which is modulated by 
specific miRNA. These findings were further confirmed by SIRT1 forced-
expression in ECs, which showed reduced FN expression in high glucose. We 
have shown that miR-195 regulates SIRT1 mediated FN alteration, further 
establishing the importance of such mechanisms of tissue damage and potential 
therapeutic role in diabetic retinopathy. 
To our knowledge, there is no previous work characterizing the role of 
miR-195 in diabetic retinopathy. Our findings are in keeping with previous reports 
regarding miR-195 where it was found to prevent palmitate-induced 
cardiomyocyte apoptosis and was elevated in liver and kidney of diabetic animals 
and in circulation of glucose intolerant patients [36-40]. It is to be noted that there 
are other SIRT1 targeting miRNAs which were not investigated. In keeping with 
such notion, in our array analysis, we noted that some SIRT1 targeting miRNAs 
were downregulated (Table 3.1). Exact significance of such changes is not clear 
and biological relevance remains to be established. Specific investigations are 
required to establish whether such alterations may represent counter-regulatory 
mechanism(s). Nevertheless, data from our study indicate that miR-195 may 
represent a major miRNA, modulating SIRT1 activity in the context of early 
diabetic retinopathy.   
There are enormous evidences on the diverse role of miRNAs in various 
physiological and pathological conditions; and have been associated in many 
cellular processes including feedback loops for various signal transduction 
pathways [27-34].  Interestingly, in a model of tumour angiogenesis, miR-195 has 
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been shown to be decreased causing upregulation of VEGF [50]. Hence, it 
appears that molecular mechanisms regarding miRNAs regarding VEGF 
regulation may vary from tumoral to non-tumoral angiogenesis. It is also possible 
that in diabetic retinopathy, additional mechanisms such as miR-195 mediated 
reduced SIRT1 causing increased p300 and histone acetylation may lead to 
increased VEGF production [10, 26]. Hence a complex interaction of miRNAs 
and other epigenetic mechanism, such as histone acetylation may be involved in 
specific protein production. Other miRNAs, eg. miR200b has also been shown to 
regulate VEGF in diabetic retinopathy [42]. Nevertheless, as deregulation of 
miRNAs lead to a variety of diseases, miRNAs have the potential to be used as 
drugs. RNA based therapies are potentially advantageous due to their specificity. 
Therefore, targeting few miRNAs in combinational therapy holds the potential to 
prevent multiple gene expressions in a multifaceted disease like diabetic 
retinopathy.  
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Chapter 4  
 
4 SIRT1 causes renal and retinal injury in diabetes 
through endothelin 1 (ET-1) and transforming 
growth factor beta 1 (TGF-β1)  
 
Rokhsana Mortuza, Biao Feng and Subrata Chakrabarti.Department of 
Pathology, Schulich School of Medicine & Dentistry,  University of Western 
Ontario, London ON Canada. 
 
 
In this study our aim was to investigate the effect of SIRT1 overexpression 
in the organ damage in diabetic animals. We examined SIRT1 mediated 
regulation of ET-1 and TGF-β1 in the renal and retinal tissues of the transgenic 
mice with diabetes.   
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4.1 Introduction 
 
Diabetes and its complications are a growing concern worldwide [1]. 
Number of people being diagnosed with diabetes in North America is increasing 
in an alarming rate [1]. Dysfunction of vascular endothelium caused by 
hyperglycemia in diabetes is the key initiating factor in the development of all 
chronic diabetic complications including diabetic nephropathy and retinopathy [2, 
3]. A structural hallmark of chronic diabetic complication is vascular basement 
membrane thickening and renal mesangial expansion, due to an increased 
production of extracellular matrix (ECM) proteins such as fibronectin (FN) and 
collagen. Although other cells may take part in such process, endothelial cells 
(ECs) lining the blood vessels play a major role [2-5].  
In diabetes glucose-induced increased oxidative stress activates several 
signaling pathways altering crucial gene expressions in the ECs [6, 7]. We and 
others have previously shown that endothelin-1 (ET-1) and transforming growth 
factor β1 (TGF-β1) are increased in circulation of patients and in organs of the 
animals with diabetes [2, 8-14]. ET-1 is a potent mitogen and vasoconstrictor that 
plays a major pathogenic role in diabetic complications by altering the blood flow, 
increasing vascular permeability and ECM protein production [8-13]. TGF-β1 is a 
cytokine belonging to a large family of regulatory proteins and in recent years has 
been evolved as one vital regulator of ECM protein production in diabetes [2, 8-
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14]. Increased TGF-β1 alters ECM protein synthesis and degradation, a delicate 
balance that is lost in diabetes causing fibrosis in the affected tissues [2, 14]. We 
have previously shown that diabetes-induced upregulated ET-1 and TGF-β1 
levels causes increase production of ECM proteins in ECs and tissues of diabetic 
animals [2, 8-14]. Moreover, we have demonstrated transcriptional co-activator 
and histone acetyl transferase (HAT) p300 interacts with transcription factors 
NFκB and AP-1 to regulate the expression of these genes [15-19]. 
SIRTs (silent information regulator proteins) are a group of NAD 
dependent class III histone deacetylases (HDACs) that regulate epigenetic gene 
silencing. SIRTs deacetylase not only histones but also many proteins and 
transcription factors. SIRT1 is the leading enzyme in the SIRT family residing 
both in the cytoplasm and nucleus. SIRT1 has been found to play crucial role in 
cellular oxidative stress response, metabolism, differentiation, longevity and 
various diseases including diabetes [20-23]. SIRT1 being a deacetylase also has 
a regulatory relationship with p300 [20].  
We investigated the role of SIRT1 and its relationship with p300 in 
regulating ET-1 and TGF-β1 and their possible downstream consequences in 
ECs and tissues of animals affected by diabetes. To this extent, we used human 
microvascular ECs (HMECs) for in vitro inspections of glucose-induced 
endothelial alterations. We further expanded the study using SIRT1 
overexpressing transgenic mice in which we induced diabetes with streptozotocin 
(STZ) and examined their renal and retinal tissues.  
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4.2 Materials and methods 
 
4.2.1 Cell culture 
 
Dermal-derived human microvascular endothelial cell (HMEC) was 
obtained (Lonza, Walkersville, MD) and grown in endothelial cell basal medium 2 
(EBM-2, Lonza, Walkersville, MD). Human embryonic kidney (HEK293A) cells 
were obtained from ATCC (Manassas, VA). We have previously described the 
culture conditions of these cells [24-27]. The glucose concentration in the growth 
medium was 5 mmol/L.  No insulin was present in any media. All cells were 
maintained in a humidified atmosphere containing 5% CO2 and at 370C 
incubation. Cells were treated with normal glucose (NG, 5 mmol/L) or high 
glucose (HG, 25 mmol/L D-glucose) or osmotic control (OSM, 25 mmol/L L-
glucose).  All reagents were obtained from Sigma Chemicals (Sigma, Oakville, 
ON) unless specified otherwise. Experiments were conducted with 6-10 
biological replicates.  
4.2.2 Animal experiments 
 
SIRT1 transgenic mice (C57BL/6-Actbtm3.1(Sirt1)Npa/J), male, 8 weeks old 
were obtained (Jackson Laboratory, Bar Harbor, ME) and genotyped with Real 
Time RT-PCR. Diabetes was induced by single intra-peritoneal injection of 
streptozotocin (STZ, 65 mg/kg in citrate buffer). Age and sex matched mice were 
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used as controls and received equal volume of citrate buffer. Diabetes was 
defined in the animals with blood glucose level >20mmol/L on two consecutive 
days (Abbott Diabetes Care, Saint-Laurent, QC). The animals were fed on a 
standard rodent diet with water ad libitum and sacrificed after 2 months following 
the development of diabetes (n = 10/group).  Urinary micro-albumin (Exocell, 
Philadelphia, PA) was measured as per the kit instructions. Retina and kidney 
tissues were collected and snap frozen in liquid nitrogen for histology. All tissues 
were stored at −80°C until further analysis.  
All animal experiments were performed in accordance with regulations 
specified by the Canadian Council of Animal Care. All protocols were approved 
by the University of Western Ontario Animal Care and Veterinary Service. The 
investigation was in compliance with the Guide for the Care and Use of Laboratory 
Animals (NIH publ. no. 85-23, revised 1996). 
4.2.3 SIRT1 enzyme activity assay 
 
Whole cell lysate were collected following treatment with RIPA buffer 
(Millipore, MA) with addition of protease inhibitor (Roche, Laval, QC). The total 
protein concentrations of the samples measured using a commercially available 
BCA protein assay kit (Pierce, Rockford, IL).Enzyme assay for SIRT1 activity 
was performed as per the manufacturer instructions (Sigma, Oakville, ON). The 
assay procedure is based on a two-step enzymatic reaction. In the first step 
SIRT1 deacetylates the substrate that contains an acetylated lysine side chain. In 
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the following step the deacetylated substrate is cleaved by the developing 
solution and a highly fluorescent group is released. This measured fluorescence 
is directly proportional to the deacetylation activity of the enzyme of the sample. 
In short 35 µl of assay buffer was added to each well following which 10 µl of 
sample and 5 µl of NAD+ was added. Adding to that 10 µl of SIRT1 substrate 
solution was added and incubated at 37oC for 30 minute. Following this 5 µl of 
developing solution was added and plate was incubated at 37oC for 10 minute. 
The plates were read with a fluorescent spectrophotometer (Biotek, Winooski, 
VT) at excitation 340 nm and emission 430 nm. 
4.2.4 mRNA extraction and cDNA synthesis 
 
RNA from cells was isolated using TRIZOL™ (Invitrogen, Burlington, ON) 
reagent as established at our laboratory. Briefly RNA was extracted with 
chloroform followed by centrifugation to separate the sample into aqueous and 
organic phases. The RNA was recovered from the aqueous phase by isopropyl 
alcohol precipitation and suspended in DEPC water. RNA concentration was 
assessed on a spectrophotometer (Gene Quant-Pharmacia Biotech, Cambridge, 
MA). First-strand cDNA was made by using High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Foster City, CA) according to the 
manufacturer instruction. The resulting products were stored at −20°C until 
further analysis by Real Time RT-PCR. 
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4.2.5 mRNA analysis with Real Time RT-PCR 
 
Real time RT-PCR was performed in LightCycler™ (Roche Diagnostics, 
Laval, QC) to quantify the mRNA expression of SIRT1 and using the Qiagen One 
Step RTPCR kit (detection platform SYBR Green I). All of the primers were either 
ordered or custom made from Sigma (Table 4.1). For a final reaction volume of 
20 µl, the following reagents were added: 4.4 µl of H2O, 10 µl of SYBR (Sigma, 
Oakville, ON), 1.6 µl of MgCl2, 1 µl forward/reverse primer and 2 µl of cDNA. To 
optimize the amplification of the genes, melting curve analysis (MCA) was used 
to determine the melting temperature (Tm) of specific products and primer dimers. 
According to the Tm value of specific products for respective genes, an additional 
step (signal acquisition step, 2–3 °C below Tm) was added following the 
elongation phase of RT-PCR. The data were normalized to housekeeping gene 
18sRNA to account for differences in reverse transcription efficiencies and the 
amount of template in the reaction mixtures.  
Table 4.1 Oligonucleotide sequences for Real Time RT-PCR. 
Name of Primer Sequence (5’ to 3’) 
Collagen Iα(I) (human) GAGGGCCAAGACGAAGACATC 
CAGATCACGTCATCGCACAAC 
ET-1 (human) AAGCCCTCCAGAGAGCGTTAT 
CGAAGGTCTGTCACCAATGT 
6FAM-TGACCCACAACCGAG-GBNFQ 
ET-1 (mice) TTAGCAAGACCATCTGTGTG 
GAGTTTCTCCCTGAAATGTG 
SIRT1 (human/mice) GCAGATTAGTAGGCGGCTTG 
TCTGGCATGTCCCACTATCA 
P300 (human) GGGACTAACCAATGGTGGTG 
ATTGGGAGAAGTCAAGCCTG 
P300 (mice) AGGCAGAGTAGGACAGTGAA 
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CTCAGTCTGGGTCACTCAAT 
TGF-β1 (human) GCCCACTGCTCCTGTGACA 
CGGTAGTGAACCCGTTGATGT 
6FAM-CAGGGATAACACACTGC-MGBNFQ 
TGF-β1 (mice) TGGAGCAACATGTGGAACTC 
GTCAGCAGCCGGTTACCA 
18s (human/mice) GTAACCCGTTGAACCCCATT 
CCATCCAACGGTAGTAGCG 
′ 
4.2.6 Adenoviral overexpression of SIRT1 and SIRT1 gene silencing 
 
SIRT1 adenovirus was obtained (ABM, Richmond, BC) and amplified in 
HEK293A cells. HMECs were transfected with the adenovirus as described 
earlier [24].  To silence SIRT1, transfection of small interfering RNA (siRNA) was 
performed using N-TER nanoparticle siRNA transfection system (Sigma, 
Oakville, ON) as described previously [20, 27]. Transfection efficiency was 
assessed by Real Time RT-PCR. 
4.2.7 p300 gene silencing  and p300 overexpression 
 
siRNA was used to specifically silence the p300 expression in ECs as 
described by us previously [20]. P300 overexpression was achieved with 
expression vectors (generously provided by Dr. Joan Boyes, The Institute of 
Cancer Research, London, UK) containing the wild-type p300 (pCI-p300) and its 
HAT-deletion mutant (pCI-p300 HAT∆1472–1522) as described earlier [15]. 
Transfection efficiency was assessed by measuring p300 mRNA expression by 
Real Time RT-PCR. 
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4.2.8 ET-1, TGF-β1 & FN ELISA 
 
ET-1 ELISA (Enzo, Farmingdale, NY) and TGF-β1 ELISA (eBioscience, 
San Diego, CA) was done on cell and tissue lysate as per the manufacturer 
instructions. FN ELISA (abcam, Toronto, ON) was done on tissue lysate as per 
the manufacturer instructions. The total protein concentrations were measured by 
BCA protein assay kit (Pierce, Rockford, IL). The plate was read at 450 nm using 
a plate reader (Multiskan, Thermofisher, Toronto, ON).  
4.2.9 Total ROS/RNS assay 
 
Total ROS/RNS (reactive oxygen species/reactive nitrogen species) assay 
(Cell Biolab, San Diego, CA) on tissue lysate was measured as per the 
manufacturer instructions. The plates were read with a fluorescent plate reader 
(Biotek, Winooski, VT) at excitation 480 nm and emission 530 nm.   
4.2.10 Endothelial permeability assay 
 
HMECs were seeded onto inserts (1-mm pores) in 24-well plates, with or 
without incubation with specific reagents for 24 h, and were tested for vascular 
permeability using the In Vitro Vascular Permeability Assay Kit (Millipore, 
Billerica, MA) according to the manufacturer’s instructions. 
4.2.11 Western blotting   
 
125 
 
The western blot analysis was conducted according to the standard 
protocol established at our lab [15] using acetylated H3 lysine (Epigentek, 
Farmingdale, NY) & β-actin antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA). 
4.2.12 Statistical analysis  
 
Data are expressed as mean ± SEM, normalized to controls. The 
statistical significance of the results was analyzed by one way or two way 
ANOVA followed by Tukey’s HSD post hoc correction and the two tailed Students 
t test as appropriate (PASW Statistics 18, IBM, Canada). A p value < 0.05 was 
considered statistically significant. 
 
4.3 Results 
 
4.3.1 SIRT1 regulates ET-1 and TGF-β1 expressions in the ECs in 
high glucose.  
As microvascular ECs are the major target of glucose-induced organ 
damage, we investigated HMECs exposed to 5 (NG) and 25 (HG) mmol/L 
glucose for 72 hrs. These concentrations are based on our previous dose 
dependent analysis of SIRT1 levels [20, 24]. Quantitative Real Time RT-PCR 
analysis of the ECs showed significant upregulation of ET-1 and TGF-β1 mRNA 
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levels (Figure 4.1A,C) and downregulation of SIRT1 mRNA levels (Figure 4.1E) 
with HG compared to NG. No effects were seen following incubation with osmotic 
control (25mmol/L of L-glucose, OSM) (Figure 4.1A,C,E). These findings were 
further reflected in ET-1 and TGF-β1 protein analysis and SIRT1 enzyme activity 
analysis, which showed a marked increase of ET-1 and TGF-β1 protein levels 
(Figure 4.1B,D) and reduced SIRT1 enzyme activity levels (Figure 4.1F) in these 
cells following HG treatment (compared to NG).  
 
Figure 4.1 SIRT1 regulates ET-1 and TGF-β1 expression in ECs. Human 
Microvascular Endothelial cells (HMECs) exposed to 25 mmol/L (HG) glucose 
compared to 5 mmol/L glucose (NG) showed increased (A) ET-1 mRNA, (C) 
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TGF-β1 mRNA and reduced (E) SIRT1 mRNA expressions. Such changes were 
not seen when the cells were incubated with 25 mmol L-glucose (osmotic control, 
OSM). Transfection of endothelial cells with Ad-SIRT1 (but not the null vector) 
increased (F) the enzyme activity in treated cells and normalized glucose-
induced upregulation of (A, C) ET-1 and TGF-β1 mRNA and  (B, D) protein 
levels. Glucose-like effects (ET-1, TGF-β1upregulation) were further seen when 
cells in NG were transfected with SIRT1 siRNA (A, C, E) but not with scramble 
siRNA. Such knockdown of SIRT1 significantly reduced (F) the enzyme activity in 
NG and increased the (B) ET-1 and (D) TGF-β1 protein levels in these cells. (*= 
significantly different from NG, ǂ= significantly different from HG, mRNA levels 
are expressed as a ratio of 18s. All data were normalized to NG). 
 
 We then proceeded to explore any relationship, between the observed glucose-
induced downregulation of SIRT1 and upregulation of ET-1 and TGF-β1 
expressions in these ECs. For this purpose, we analysed the ECs following 
transfection with SIRT1 adenovirus (Ad-SIRT1). Transfection efficiency was 
measured with Real Time RT-PCR and confirmed with SIRT1 enzyme analysis 
(Figure 4.1E,F). We noted the Ad-SIRT1 transfection significantly increased the 
SIRT1 mRNA and enzyme levels in the ECs in HG (Figure 4.1E,F). Most 
importantly, this transfection caused a significant reduction in ET-1 and TGF-β1 
mRNA and protein levels in these ECs in HG (Figure 4.1A-D). ECs transfected 
with null vector did not show such change (Figure 4.1A,C).  
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In addition, SIRT1 knockdown with siRNA (efficiency in Figure 4.1E,F) in NG 
mimicked the effects of HG, causing an increase in ET-1 and TGF-β1 levels in 
these ECs (Figure 4.1A-D). Conversely, ECs transduced with scramble siRNA 
did not show these changes (Figure 4.1A-D). These results demonstrated a 
SIRT1 mediated regulation of ET-1 and TGF-β1 in the ECs in hyperglycemia. 
4.3.2 SIRT1 regulates ET-1 and TGF-β1 expressions via p300. 
In order to investigate the mechanism of such SIRT1 mediated ET-1 and 
TGF-β1 regulation we looked at transcriptional co-activator p300, as we 
previously have found SIRT1 and p300 balance each other [20]. In keeping with 
the earlier findings we noted SIRT1 overexpression with adenovirus in 25 mmol/L 
glucose normalizes glucose-induced augmented p300 mRNA levels (Figure 
4.2A). On the contrary, SIRT1 knockdown in NG with siRNA caused an increase 
in p300 mRNA levels (Figure 4.2A). Furthermore, p300 overexpression in these 
cells in NG reduced the SIRT1 mRNA levels (Figure 4.2B,C). These changes 
were not seen with null vector, scramble siRNA and p300 mutant transfections. 
These results re-established a regulatory and balancing role of SIRT1 and p300 
on each other in ECs. 
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Figure 4.2 SIRT1 regulates ET-1 and TGF-β1 via p300. HG caused increased (A) 
p300 mRNA and reduced (B) SIRT1 mRNA levels in ECs. (A) Ad-SIRT1 
transfection in HG prevented p300 upregulation and SIRT1 knockdown with 
siRNA in NG upregulated p300 mRNA levels. (B) p300 siRNA transfection in HG 
(efficiency in A) normalized SIRT1 expression. Furthermore p300 overexpression 
in NG (efficiency in A) reduced SIRT1 mRNA levels. (C, D) HG induced ET-1 and 
TGF-β1 upregulation was abrogated with p300 siRNA (not with scramble) 
transfection. p300 overexpression in NG upregulated the expressions of these 
transcripts.  (E, F) Rescue experiment showing upregulation of ET-1 and TGF-β1 
mRNA levels in NG with SIRT1 knockdown can be resolved with subsequent 
p300 knockdown in the ECs. (NG= 5 mmol/L glucose, HG= 25 mmol/L glucose, 
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OSM = osmotic control, *= significantly different from NG, ǂ= significantly 
different from HG, mRNA levels are expressed as a ratio of 18s. All data were 
normalized to NG). 
 
To confirm the downstream effects of such changes we examined the cells 
following knockdown of p300 with siRNA (efficiency in Figure 4.2B) in HG.  Such 
treatment not only normalized the SIRT1 mRNA levels (Figure 4.2C) but also 
reduced the ET-1 and TGF-β1 mRNA levels in HG (Figure 4.2D,E) compared to 
scrambled controls. In addition, p300 overexpression in NG lead to an increased 
mRNA levels for both ET-1 and TGF-β1 mimicking the HG treatments (Figure 
4.2D,E). P300 mutant transfected cells did not show such change. These results 
further establish that SIRT1 regulates ET-1 and TGF-β1 through p300. 
We further conducted a rescue experiment to confirm such pathway. We first 
knocked down SIRT1 with siRNA in NG in these ECs, following which we 
transfected the cells with p300 siRNA. Transfection efficiency assessed with Real 
Time RT-PCR showed reduction of both SIRT1 (88%) and p300 (61%) mRNA 
levels in the treated cells. We noted such transfection prevented the ET-1 and 
TGF-β1 mRNA upregulation in the treated cells (Figure 4.2F). 
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4.3.4 SIRT1 overexpression prevent glucose-induced increased 
endothelial permeability and collagen Iα(I) expression. 
 To investigate the functional consequences of SIRT1 mediated ET-1 and 
TGF-β1 regulation we conducted trans-endothelial permeability assay as 
increased endothelial permeability is a characteristic alteration in early diabetic 
microangiopathy. Data from the In vitro permeability test showed HG significantly 
increases ECs permeability and Ad-SIRT1 transfection prevented such leakage 
in these cells (Figure 4.3A,B). P300 siRNA transfection in HG also had similar 
effect showing reduction in glucose-induced leakage whereas; SIRT1 knockdown 
or p300 overexpression in NG both significantly increased the ECs permeability 
mimicking the HG (Figure 4.3A,B).  
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Figure 4.3 SIRT1 overexpression prevents glucose-induced increased 
endothelial permeability and collagen Iα(I) expression. A) Duration dependent 
endothelial permeability and (B) end point analysis showed, HG induced 
increased endothelial permeability was prevented by Ad-SIRT1 transfection or 
p300 siRNA treatment. SIRT1 siRNA or p300 overexpression in NG caused 
increased permeability by these cells mimicking the effects of HG. (C) HG 
caused an increase in Collagen Iα(I) mRNA expression in the ECs which was 
prevented by Ad-SIRT1 or p300 siRNA transfection. Opposingly, SIRT1 
knockdown or p300 overexpression both lead to an upregulation of Collagen Iα(I) 
mRNA levels in NG. (D) Western blot analysis of acetylated histone (Ac-
H3K9/14) shows Ad-SIRT1 or p300 siRNA transfection reduced HG-induced 
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increased histone acetylation in HMECs. On the other hand SIRT1 siRNA or 
p300 overexpression increased such acetylation in NG in these ECs. (NG= 5 
mmol/L glucose, HG= 25 mmol/L glucose, *= significantly different from NG, ǂ= 
significantly different from HG. HMECs= human microvascular endothelial cells. 
mRNA levels are expressed as a ratio of 18s. All data were normalized to NG). 
 
Previously we have shown SIRT1 overexpression prevented glucose-induced FN 
upregulation in the ECs [27]. We further examined collagen Iα(I) expression 
levels following HG exposure. With Ad-SIRT1 transfection, we observed a 
normalization of glucose-induced upregulation of collagen Iα(I) mRNA levels 
(Figure 4.3C).  HG induced increased collagen Iα(I) mRNA expression was 
further prevented by p300 siRNA transfection (Figure 4.3C). In parallel, SIRT1 
knockdown or p300 forced expression both caused an upregulation of collagen 
Iα(I)  mRNA levels in NG (Figure 4.3C). Moreover, we conducted western blot 
analysis of acetylated histone (Ac-H3K9/14) to see the functional consequences 
of p300 and SIRT1 alteration. Such analysis showed HG-induced increased Ac-
H3K9/14 was reduced with Ad-SIRT1 or p300 siRNA transfection (Figure 4.3D). 
Opposingly, SIRT1 siRNA or p300 forced expression in NG increased such 
acetylation in the ECs. These experiments together provide further evidence that 
SIRT1 regulate ET-1 and TGF-β1 through p300. 
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4.3.5 SIRT1 regulate ET-1 and TGF-β1expressions in the kidney and 
retina of diabetic mice. 
Following the establishment that SIRT1 regulated ET-1 and TGF-β1 in 
ECs, we expanded our study to investigate whether the mechanisms seen in 
these cells was important in the development of renal and retinal 
microangiopathy in a well-established animal model. STZ- induced diabetic mice 
showed hyperglycemia (diabetics 21.91±4.58 mmol/L vs controls 7.38±0.91 
mmol/L, P<0.001) and reduced body weight (diabetics 22.80±1.40 g. vs controls 
30.25±2.36 g., P<0.001).  Initially we performed Real Time RT-PCR analysis of 
the renal and retinal tissue from these mice following 2 months of uncontrolled 
diabetes. We have previously shown that diabetes induced increased ECM 
protein and vasoactive factor expression is established at this time point [19, 20, 
24-27]. mRNA analysis showed diabetic mice had significant downregulation of 
SIRT1 expressions in the kidneys and retinas (Figure 4.4A,B). This finding was 
further reflected in the SIRT1 enzyme activity levels (Figure 4.4C,D). Moreover, 
these mice showed significant upregulation of p300 mRNA levels in the renal and 
retinal tissues which were abrogated in SIRT1 overexpressing diabetic mice 
(Figure 4.4E,F). Western blot analysis further showed SIRT1 overexpression 
caused reduction in histone acetylation (Ac-H3K9/14) in these tissues 
demonstrating the downstream functional consequences of p300 alteration in 
these tissues (Figure 4.4G).  
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Figure 4.4 SIRT1 overexpressing diabetic mice shows reduced p300 expressions 
in the kidney and retina. Transgenic mice with SIRT1 overexpression (SIRT1 Tg) 
showed increased expressions of (A, B) SIRT1 mRNA levels and (C, D) enzyme 
activity in the kidneys and retinas of diabetic and control animals.  Such 
overexpression averted diabetes-induced increased (E, F) p300 mRNA levels 
and (G) histone acetylation (Ac-H3K9/14) in these tissues. (Co= Control, 
Di=Diabetic, *= significantly different from control, ǂ= significantly different from 
Diabetic. mRNA levels are expressed as a ratio of 18s. All data were normalized 
to Co). 
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We further looked at ET-1 and TGF-β1 levels in these mice. SIRT1 
overexpressing diabetic mice showed significantly reduced level of ET-1 and 
TGF-β1 mRNA levels compared to diabetic mice in both tissues (Figure 4.5A-D). 
We further confirmed these results using ELISA which showed diabetes-induced 
increased ET-1 and TGF-β1 protein levels in the renal and retinal tissues are 
significantly reduced with SIRT1 overexpression in these tissues (Figure 4.5E-H).  
 
Figure 4.5 SIRT1 regulates ET-1 and TGF-β1 expressions in kidney and retina of 
diabetic mice. SIRT1 overexpression was protective against diabetes-induced (A, 
B) ET-1 and (B, C) TGF-β1 mRNA upregulation in the kidneys and retinas of 
mice.  In keeping with the mRNA expressions SIRT1 transgenic mice (SIRT1 Tg) 
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with diabetes showed reduced (E, F) ET-1 and (G, H) TGF-β1 protein levels in 
these tissues compared to the wild type diabetic mice. (Co= Control, Di= 
Diabetic, *= significantly different from control, ǂ= significantly different from 
Diabetic. mRNA levels are expressed as a ratio of 18s. All data were normalized 
to Co). 
 
4.3.6 SIRT1 overexpression prevents diabetes-induced micro-
albuminuria and FN upregulation in tissues.  
To examine the downstream consequence of SIRT1 mediated alteration of 
ET-1 and TGF-β1 in diabetes, we investigated urinary micro-albumin levels to 
assess renal function in these mice. Diabetic mice showed increased micro-
albuminuria compared to controls indicating poor kidney function in these 
animals (Figure 4.6A). SIRT1 overexpression significantly reduced micro-
albuminuria and diabetes-induced increased collagen Iα(I) mRNA expression by 
the transgenic diabetic animals (Figure 4.6A,B). Furthermore in the renal and 
retinal tissues of the diabetic animals such overexpression reduced diabetes-
induced increased FN protein and total ROS/RNS levels (Figure 4.6C,D). These 
results suggest that SIRT1 has a protective role against diabetes-induced renal 
and retinal damages. 
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Figure 4.6 SIRT1 transgenic mice shows improved renal function and reduced 
oxidative stress and FN upregulation with diabetes. (A) SIRT1 overexpression 
prevented diabetes-induced micro-albuminuria in mice. Furthermore such 
overexpression averted diabetes-induced increased (B) collagen Iα(I) mRNA  
expression (C) FN protein and (D) total ROS/RNS levels in the renal and retinal 
tissues. (SIRT1 Tg= SIRT1 transgenic mice, Co= Control, Di= Diabetic, *= 
significantly different from control, ǂ= significantly different from Diabetic. mRNA 
levels are expressed as a ratio of 18s. All data were normalized to Co). 
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4.4 Discussion 
In this study we have shown that SIRT1 regulates glucose induced 
overexpression of ET-1 and TGF-β1 in the ECs. We have also shown that SIRT1 
regulates ET-1 and TGF-β1 levels in the kidneys and retinas of diabetic animals. 
In addition we have demonstrated such processes are regulated through 
transcriptional co-activator p300. Using adenoviral overexpression of SIRT1 and 
knockdown of SIRT1 with siRNA, we have directly demonstrated that glucose-
induced ET-1 and TGF-β1 upregulation can be markedly reduced by increasing 
the availability of SIRT1. In the kidneys and retinas of SIRT1 overexpressing 
transgenic mice we have further established the existence of such regulation in a 
STZ- induced type 1 model of diabetes. To be best of our knowledge, such 
SIRT1 mediated regulation of ET-1 and TGF- β1 in diabetic complications have 
not been shown earlier. 
In diabetes, high oxidative stress due to hyperglycemia causes DNA 
damage and activates several transcription and vasoactive factors altering crucial 
gene expressions [2, 6, 7]. Here we describe the role of SIRT1 causing 
protection against ET-1 and TGF-β1 induced endothelial damage in 
hyperglycemia. We initially demonstrated SIRT1 downregulation in parallel to ET-
1 and TGF-β1 upregulation in glucose exposed ECs. Then, we directly 
demonstrated its functional significance in terms of endothelial permeability and 
collagen Iα(I) expression and the relationship with p300 in these cells. In keeping 
with our earlier findings here we have shown that acting in opposing manner, 
p300 and SIRT1 regulate each other in hyperglycemia. We further showed the 
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functional significance of this mechanism in an animal model of diabetic 
microangiopathy. 
Although there is no previous work showing SIRT1 mediated regulation of 
ET-1 or TGF-β1 expressions, SIRT1 has been found to regulate downstream 
effectors of TGF-β1 via deacetylation of SMAD7 [28]. This study demonstrates a 
SIRT1 mediated regulation of TGF-β1 expressions which signals through 
SMADs. One of the major glucose-induced endothelial dysfunctions includes 
augmented ECM protein production [2-14]. Increased ECM proteins are 
deposited in the tissue which is manifested as structural changes such as 
basement membrane thickening, mesangial expansion etc. We and others have 
demonstrated glucose-induced increased collagen and FN synthesis in the 
endothelial cells and in the retina, kidney and heart in diabetes [2-19]. We have 
also demonstrated that glucose induced ECM protein upregulation is mediated 
through p300-dependent histone acetylation and p300 binds to the promoter 
regions of ET-1 and FN genes [15-19]. In this study we have shown one further 
step of p300 mediated regulation of ET-1 and TGF-β1 in ECs and tissues of 
diabetic animals. We have shown that by modulating SIRT1 we can prevent such 
glucose induced damages.   
ET-1 and TGF-β1 are two important cytokines playing key roles in tissue 
damage in diabetic complications. It is of interest to note that such SIRT1 
induced regulation is mediated through p300. P300 as a transcriptional co-
activator is potentially capable of altering multiple transcripts [15, 18, 19]. This 
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study shows it is possible to target either SIRT1 or p300 to prevent diabetes-
induced alterations. We have previously shown that p300 is regulated by miR-
200b and it regulates miR-146a [24, 26]. Additionally we have shown that miR-
195 regulates SIRT1 expression [27]. In this assumption we showed a ying-yang 
relationship between p300 and SIRT1. Hence a complex web connecting multiple 
such epigenetic processes involving acetylators, deacetylators, miRNAs and 
other undetermined epigenetic process may ultimately dictate expression of 
specific transcripts. It is also possible that SIRT1 may influence several other 
inflammatory cytokines which are of importance in the context of nephropathy 
and retinopathy and other chronic diabetic complications. However, such roles of 
SIRT1 in these processes need to be established in future through specific 
experiments. 
The pathogenic mechanisms leading to chronic diabetic complications are 
complex. Several vasoactive and growth factors are simultaneously activated in 
response to hyperglycemia and an intricate interplay occurs among such factors 
[2-20, 24-26]. The findings of this study indicate that SIRT1 is a protective 
molecule in diabetic nephropathy and retinopathy. Loss of SIRT1 production 
represents a key event in the pathogenesis of chronic diabetic complications. 
Hence SIRT1 holds the potential to be used as a drug target for the treatment of 
chronic diabetic complications. 
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Chapter 5  
 
5 Thesis summary and future directionsc 
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5.1 Overall findings 
 
 The major contributor of vascular diabetic complications is damage to the 
ECs [1-22]. Hyperglycemia induced increased oxidative stress causes ECs to 
secrete large amount of vasoactive factors, growth factors and cytokines [1-22]. 
These factors lead to structural and functional changes in the ECs such as 
increased permeability and basement membrane thickening [1-22]. We and 
others have previously shown that glucose-induced increased oxidative stress 
alters expression of several genes ultimately causing increased production of 
ECM proteins by the ECs such as collagen and FN [1-22]. Interestingly some of 
these above mentioned changes are also seen in normal vascular aging [23-37]. 
Hence in this study we asked whether hyperglycemia in diabetes accelerates 
aging-like process in ECs and tissues of diabetic animals (chapter 2).   
 To create an aging-like in vitro process, we continuously propagated ECs 
of three different origins (HMEC, BREC and HUVEC) in high and normal glucose 
and examined for signs of cellular senescence and oxidative stress. We found 
oxidative stress in hyperglycemia accelerated aging-like changes in ECs. 
However such processes were variable among the various ECs. Microvascular 
ECs were more susceptible to glucose induced rapid aging compared to large 
vessel ECs. As we looked into the mechanism behind such aging process we 
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found SIRT enzymes were reduced in the aged cells. Glucose-induced increased 
oxidative stress caused reduction of mitochondrial antioxidant enzymes in a 
SIRT1 and FOXO1 mediated pathway. Moreover level of SIRT1 was negatively 
regulated by p300, a HAT and transcriptional co-activator. Using activators of 
SIRT1 we were able to effectively prevent such aging-like changes in the ECs. In 
addition, examination of kidneys and retinas of diabetic mice showed that 
diabetes causes rapid aging in these tissues. Such changes were associated 
with increased oxidative stress and reduced SIRT1 enzyme levels. Overall we 
have found an important role played by SIRTs in such process. We showed an 
important mechanistic pathway of oxidative stress and aging in HG, mediated 
through FOXO1 and regulated by SIRT1 and p300 (chapter 2).   
Next we investigated regulation of SIRT1, specially by miRNAs (chapter 
3). miRNAs are post transcriptional regulators of genes. miRNAs are conserved 
non-coding RNAs and are highly specific in nature, hence holds tremendous 
potential to be used as therapeutic targets. Several miRNAs have been found to 
regulate SIRT1 in various physiological and pathological conditions. In this study 
we examined alteration of SIRT1 targeting miRNAs in the retinal tissues of 
animals with diabetes.  
Our initial microarray analysis showed miR-195, a SIRT1 targeting miRNA 
was significantly overexpressed in the retinas of diabetic animals. We then 
validated such findings in two different type of microvascular ECs. This was 
associated with reduced SIRT1 levels in these cells. We then examined the 
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possible miR-195 mediated regulation of SIRT1 at multiple levels of complexities 
in the context of diabetic retinopathy. 
We used miR-195 antagomir, mimic and adenovirus with SIRT1 
overexpression to identify in vitro biological significance. We found miR-195 
antagomir transfection significantly upregulated SIRT1 levels in the ECs. Such 
transfection further prevented SIRT1 mediated aging changes and reduced 
glucose-induced increased FN levels in the ECs. SIRT1 overexpression in high 
glucose showed similar effect whereas miR-195 mimic transfection in NG 
mimicked the high glucose effect. We also showed similar alterations and its 
functional significance in an animal model of diabetic retinopathy. By injecting 
miR-195 antagomir intravitreally in STZ induced type 1 diabetic rats, we showed 
such treatment prevented SIRT1 reduction in these tissues following 1 month of 
uncontrolled hyperglycemia. Such treatment also reduced diabetes induced 
increased vascular permeability and normalized FN proteins levels. Overall in 
this study we have shown a novel role of miR-195 regulating hyperglycemia 
induced changes through SIRT1 in microvessels in diabetes. Data from this 
study indicate that miR-195 may represent a major miRNA, modulating SIRT1 
activity in the context of early diabetic microangiopathy.  
In order to explore the role of SIRT1 further and to examine whether such 
mechanisms are universal in other organs affected by diabetic complications, we 
investigated transgenic mice with SIRT1 overexpression (chapter 4). We induced 
diabetes in these mice with STZ injection and examined their kidney and retinal 
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tissues, for possible alteration of genes which are major players of diabetic 
microangiopathy. We found these transgenic mice had significantly reduced 
levels of ET-1 and TGF-β1, two major factors of vascular pathogenesis, in the 
renal and retinal tissues. This finding intrigued us to investigate a possible SIRT1 
mediated regulation of ET-1 and TGF-β1 in diabetes.  
Using adenoviral overexpression of SIRT1, we found that glucose-induced 
ET-1 and TGF-β1 upregulation can be markedly reduced by increasing the 
availability of SIRT1. Such treatment also corrected glucose-induced increased 
endothelial permeability and increased FN, collagen expressions. Moreover we 
found such SIRT1 mediated ET-1 and TGF-β1 regulation is mediated through 
transcriptional co-activator p300. We further found similar relationships in the 
SIRT1 transgenic mice with diabetes. These findings established that SIRT1 can 
provide protection against ET-1 and TGF-β1 induced endothelial damage in 
hyperglycemia. In keeping with our earlier findings we found again that p300 and 
SIRT1 regulate each other in hyperglycemic conditions and by modulating any of 
these we can prevent some glucose induced SIRT1 mediated damages.   
Together the findings of this research show a novel role played by SIRT1 in 
diabetic microangiopathy. Data from this study indicate that SIRT1 is a protective 
molecule in diabetic vascular complications and holds the potential to be used as 
a therapeutic target for the treatment of diabetes. 
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5.2 Limitations and future directions 
There is no study without limitations. In this study we have mainly focused 
on SIRT1 mediated alterations in ECs and renal and retinal tissues in diabetes. 
Whether similar changes occur in other organs affected by diabetes such as 
brain, liver, heart etc were not examined and needs further investigation. 
Furthermore, we have not looked in detail the role of other SIRTs (2-7) in 
endothelial dysfunction. As mitochondrial oxidative stress is the root cause of 
endothelial damage in diabetes, mitochondria specific SIRTs such as SIRT 3, 4, 
5 may play key role in such process and needs further investigation.  
The present study was performed on animals with type 1 diabetes. Future 
studies need to be done to see the effect of SIRT1 alteration in type 2 and 
gestational diabetes. In chapter 3 we examined the regulation of SIRT1 with miR-
195 in the context of diabetic retinopathy. We have seen miR-195 inhibitor has 
some protective benefit in such disease process mediated through SIRT1. More 
work is needed to examine if such beneficial effects are present in other target 
organs of diabetic complications.  
Although we have done several animal studies, a lot of our work is based 
on cultured ECs. ECs in cultured in vitro conditions is much simpler an 
environment than in vivo, which has more interaction between ECs, ECM 
proteins and other cells (smooth muscle cells, immune cells, fibroblasts etc). 
Furthermore though rodent models share a large percentage of their DNA with 
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humans significant differences exist. These factors should be considered before 
translating the current study to human. 
Several SIRTs share molecular targets and affect common pathogenic 
pathways. To what extent SIRTs possess unique versus redundant functions and 
the degree to which crosstalk exists between these enzymes are some of the key 
questions that need to be systematically investigated. Questions such as to what 
extent activation of all SIRTs occur as a consequence of increased cellular NAD+ 
levels or whether different SIRTS have opposing roles in a disease condition 
(such as cancer) need to be investigated. We further need to examine possible 
consequences of long term increase in SIRT activity in vivo, before considering it 
to be a viable therapy. Although overexpression of SIRTs in some specific 
contexts have been found to confer health benefits and increase longevity, in 
general it is unknown whether long-term sustained increase of SIRT activity may 
have any deleterious consequences or not.  
Finally although recently some studies investigating posttranslational 
modifications of SIRTs are emerging, further mechanistic studies on 
physiological regulation of SIRT needs to be done to gain insights into its function 
and features so that it may be used as a specific drug target. 
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Appendix-Experimental methods and materials 
 
Cell culture 
Bovine retinal microvascular endothelial cells (BRECs) were obtained from 
VEC Technologies (Rensselaer, NY) and were grown in a defined endothelial cell 
growth medium (MCDB-131 complete). The cells were passaged in 12 well plate 
(Corning, Acton, MA) coated with fibronectin (Sigma, St. Louis, MO). Dermal-
derived human microvascular endothelial cell (HMEC) was obtained from Lonza, 
Inc. (Walkersville, MD) and human retinal microvascular endothelial cells 
(HRECs) were obtained from Olaf Pharmaceuticals (Worchester, MA). HRECs 
and HMECs were grown in endothelial cell basal medium 2 (EBM-2, Lonza, 
Walkersville, MD). Human umbilical vein endothelial cells (HUVECs) were 
obtained from Clonetics (Rockville, MD, USA), were cultured in endothelial cell 
growth medium (EGM). Human embryonic kidney (HEK293A) cells were 
obtained from ATCC (Manassas, VA) and cultured as per the manufactures 
protocol. The glucose concentration in the growth medium was 5 mmol/l.  No 
insulin was present in any media. All cells were maintained in a humidified 
atmosphere containing 5% CO2 and at 370C incubation [1-7]. Reagents were 
obtained from Sigma Chemicals (Sigma, Oakville, ON) unless specified 
otherwise. 
For the long term continuous exposure to glucose, ECs were cultured in 
12 well plates (Corning, Acton, MA) and treated with 5mM glucose (NG) or 25mM 
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glucose (HG, D-glucose) or osmotic control (OSM, 25 mM L-glucose). Upon 
confluence cells were propagated & maintained in the same treatment condition 
until they stopped proliferating completely. During each passage subculture cells 
from each treatment group were stained for SA β-gal and collected for RNA 
analysis. Cells were monitored daily and images taken for morpholocigal and 
growth analysis. To test the effect of SIRT activation on accelerated aging in 
diabetes, cells were treated with 10 µM resveratrol (Sigma, Oakville, ON) 
dissolved in ethanol or with 25 µM BML278 (ENZO, Farmingdale, NY) in DMSO 
for 72 hr. To investigate the effect of FOXO1 inhibition, cells were treated with 
0.1 µM FOXO1 inhibitor AS1842856 (Millipore, Billerica, MA) in DMSO similarly 
[3].  
Cell lysates were collected with RIPA (Millipore, Billerica, MA) buffer with 
protease inhibitor (Roche, Laval, QC) for total ROS/RNS, MnSOD, ET-1, TGF-
β1, LDH, SIRT1 analysis. Total protein concentrations were measured by BCA 
protein assay kit (Pierce, Rockford, IL). All experiments were conducted with 6-
10 biological replicates [3]. 
Extraction of mRNA and cDNA synthesis 
RNA from cells was isolated using TRIZOL™ (Invitrogen, Burlington, ON). 
Then RNA was further extracted with chloroform followed by centrifugation to 
separate the sample into aqueous and organic phases. The RNA was recovered 
from the aqueous phase by isopropyl alcohol precipitation and suspended in 
DEPC water. RNA concentration was assessed on a spectrophotometer (Gene 
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Quant-Pharmacia Biotech, Cambridge, MA). First-strand cDNA was made by 
using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster 
City, CA) as per the manufacturer instruction [1-7]. The resulting products were 
stored at −20°C until further analysis by Real Time RT-PCR. 
mRNA analysis with quantitative Real Time RT-PCR 
Real time RT-PCR was performed in LightCycler™ (Roche Diagnostics, 
Laval, QC) to quantify the mRNA expression of SIRT(1-7), hTERT, p300, FN, 
ET-1, TGF-β1 and CollagenIα(I) using the Qiagen One Step RTPCR kit 
(detection platform SYBR Green I). All of the primers were either ordered or 
custom made from Sigma. For a final reaction volume of 20 µl, the following 
reagents were added: 4.4 µl of H2O, 10 µl of SYBR (Sigma, Oakville, ON), 1.6 µl 
of MgCl2, 1 µl forward/reverse primer and 2 µl of cDNA. To optimize the 
amplification of the genes, melting curve analysis (MCA) was used to determine 
the melting temperature (Tm) of specific products and primer dimers. According to 
the Tm value of specific products for respective genes, an additional step (signal 
acquisition step, 2–3 °C below Tm) was added following the elongation phase of 
RT-PCR. The additional step in the PCR reactions is allowed for signal 
acquisition from specific target products. The data were normalized to 
housekeeping gene 18sRNA or β-Actin to account for differences in reverse 
transcription efficiencies and the amount of template in the reaction mixtures [1-
7].  
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SIRT1 enzyme activity assay 
Enzyme assay for SIRT1 activity was performed on cell lysate or tissue 
homogenate as per the manufacturer instructions (Sigma, Oakville, ON). The 
assay procedure is based on a two-step enzymatic reaction. In the first step 
SIRT1 deacetylates the substrate that contains an acetylated lysine side chain. In 
the following step the deacetylated substrate is cleaved by the developing 
solution and a highly fluorescent group is released. This measured fluorescence 
is directly proportional to the deacetylation activity of the enzyme of the sample. 
In short 35 µl of assay buffer was added to each well following which 10 µl of 
sample and 5 µl of NAD+ was added. Adding to that 10 µl of SIRT1 substrate 
solution was added and incubated at 37oC for 30 minute. Following this 5 µl of 
developing solution was added and plate was incubated at 37oC for 10 minute. 
The plates were read with a fluorescent spectrophotometer (Biotek, Winooski, 
VT) at excitation 340 nm and emission 430 nm [3, 8]. 
SIRT1 gene silencing 
To silence SIRT1, transfection of small interfering RNA (siRNA) was performed 
using N-TER nanoparticle siRNA transfection system (Sigma, Oakville, ON) 
according to the manufacture’s protocol [1, 3, 9]. SIRT1 siRNA1 was purchased 
from Dharmacon Inc. (Lafayette, CO) and SIRT1 siRNA2 was purchased from 
Santa Cruz Biotecnology (Santa Cruz, CA). Cells were incubated with or without 
glucose after transfection for 24 hr and sample collected for mRNA analysis. To 
test the effect of SIRT1 siRNA on resveratrol, the siRNA was added 48 hr post 
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treatment with resveratrol in the cultured cells and samples collected 24 hr post 
transfection. The transfection efficiency was assessed by real-time RT-PCR. 
p300 gene silencing  and p300 overexpression 
To silence the p300 expression in ECs, p300 siRNA1 (Silencer, Ambion, Austin, 
TX) and p300 siRNA2 (Santa Cruz Biotechnology, Santa Cruz, CA) was used 
with siPORT Lipid transfection reagent (Ambion, Carlbad, CA). ECs were 
transfected with p300 siRNAs (100 ηmol/l) with the siRNA transfection reagent (1 
µl/500 µl transfection volume). Cells were incubated with or without glucose for 
24 hr following the transfection and collected for mRNA analysis [1, 3]. Some 
transfected cells were further treated with glucose upto passage 1 and sample 
collected for SA-βgal staining, nuclear fraction isolation and protein analysis. 
siRNA transfection efficiency was indirectly assessed by measuring p300 mRNA 
expression by real-time RT-PCR.  
P300 overexpression was achieved with expression vectors (generously 
provided by Dr. Joan Boyes, The Institute of Cancer Research, London, UK) 
containing the wild-type p300 (pCI-p300) and its HAT-deletion mutant (pCI-p300 
HAT∆1472–1522). The plasmids were transfected and amplified in DH5a 
Escherichia coli bacteria following which extracted with the QIApre Spin Miniprep 
Kit (Qiagen, Toronto, ON). HMECs were transfected with 2 µg/flask (T25) of 
plasmids with Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada) 
according to the manufacturer’s instructions [1, 3]. Cells were incubated with or 
without glucose for 24 hr following the transfection and collected for mRNA 
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analysis. Some transfected cells were further treated with glucose upto passage 
1 and sample collected for mRNA and protein analysis. Transfection efficiency 
was assessed by measuring p300 mRNA expression by Real Time RT-PCR. 
ET-1, TGF-β1 ELISA and Telomerase activity 
ET-1 ELISA (Enzo, Farmingdale, NY) and TGF-β1 ELISA (eBioscience, San 
Diego, CA) was done on cell and tissue lysate as per the manufacturer 
instructions [2, 6, 10-13]. The total protein concentrations were measured by 
BCA protein assay kit (Pierce, Rockford, IL). The plate was read at 450 nm using 
a plate reader (Multiskan, Thermofisher, Toronto, ON). Telomerase activities of 
the samples were measured using a commercially available kit following 
instructions provided by the manufacturer (Allied Biotech Inc., Germantown, MD). 
Endothelial permeability assay 
To examine endothelial permeability, the In Vitro Vascular Permeability Assay Kit 
(Millipore, Billerica, MA) was used according to the manufacturer’s instructions 
[14]. HMECs were seeded onto collagen coated inserts (1mm pores) in 24-well 
plates. Following the formation of cell monolayer (2-3 days), cells were treated 
with specific reagents (Ad-SIRT1, p300 siRNA, p300 plasmid, SIRT1 siRNA) with 
or without glucose for 72 h. After treatment FITC-Dextran is added to the cells 
and permeability of this fluorescent molecule is measured at several intervals (30 
minute, 1 hour, 1.5 hour and 2 hour). The plates were read with a fluorescent 
spectrophotometer (Biotek, Winooski, VT) at excitation 485 nm and emission 535 
nm. 
162 
 
Western blot for protein analysis 
Western blot analysis was conducted according to the standard protocol 
established at our lab [1, 3] using SIRT1, p300, Ac-FOXO1, β-actin (Santa Cruz 
Biotechnology, Santa Cruz, CA) and acetylated H3 lysine antibody (Epigentek, 
Farmingdale, NY). About 200 µg of protein was extracted from each well/tissue. 
20 µg per lane of cellular or nuclear protein was resolved by 5–10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. Signals were detected with 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) and developed with the chemiluminescent 
substrate (Amersham Pharmacia Biotechnology, Piscataway, NJ) as per the 
manufacturer instructions. 
miRNA extraction and analysis 
miRNAs were extracted from the cells and tissues using the mirVana miRNA 
isolation kit (Ambion, Inc., Austin, TX). Briefly, the cells were collected and wash 
2 times by using PBS.  The tissues were homogenized in the Lysis/Binding 
solution and miRNA additive(1:10) was added to the samples on ice for 15 
minutes. Equal volume acid-phenol: chloroform was added to cell suspension 
and the tissue lysate, and mixed for 30 seconds by vortex. Following 
centrifugation and removal of the aqueous phase, the mixture was added 1.25 
fold 100% ethanol. The mixture was passed through the filter cartridge and 
eluted with elution solution. The real-time PCR was used  with a final reaction 
volume of 20 µL containing 10 µL TaqMan 2X Universal PCR Master Mix (No 
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AmpErase UNG), 1 µL TaqMan microRNA assay (Applied Biosystems Inc, CA, 
USA), 8 µL Nuclease-free water and 1 µL RT-product. The data was normalized 
to RNU6B snRNA to account for differences in reverse-transcription efficiencies 
and amount of template in the reaction mixtures [14-16]. 
miRNA mimic or antagomir transfection  
The HMECs and HRECs were transfected with miRIDIAN microRNA-195 mimic 
or antagomir (20 nM) (Dharmacon Inc., Chicago, IL) using transfection reagent 
Lipofectamine2000 (Invitrogen, Burlington, ON). miRIDIAN microRNA mimic or 
antagomir scrambled control were used in parallel.  Transfection efficiency of 
miRNA was determined by real time RT-PCR [14-16]. 
Adenoviral forced-expression of SIRT1  
SIRT1 adenovirus (devoid of 3’UTR) and null vector was obtained from ABM 
(Richmond, BC, Canada) and amplified in HEK293A cells [16, 17]. HRECs & 
HMECs were grown in standard 6-well plates to 90% confluence. Next, cells 
were transfected with 1 ml Ad-SIRT1 or the empty vector. Subsequently, 3 mL of 
additional media was added 4 h later and the transfected cells were incubated 
with or without glucose for 72 h. Cells were either collected with RIPA buffer for 
protein analysis or TRIZOLTM (Invitrogen, Burlington, ON) for RNA analysis. 
 Luciferase Reporter Assay for Targeting SIRT1-3'UTR 
The luciferase vector including 3′UTR of SIRT1 (1080 bp) containing the SIRT1-
miR-195 response elements (wt-Luc-SIRT1) and the mutant (mu-Luc-SIRT1) 
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were purchased from Norclone Biotech Laboratories (London, ON, Canada). 
Plasmid DNA (wt-Luc-SIRT1 or mu-Luc-SIRT1, β-galactosidase control vector) 
and miR-195 mimic or scrambled oligonucleotide were co-transfected in HRECs 
for 48 hours. The luciferase activity was measured using the Dual-Light 
Chemiluminescent Reporter Gene Assay System (Applied Biosystems, 
Burlington, ON) and SpectraMax M5 (Molecular Devices, Sunnyvale, CA). The 
luciferase activity was normalized for transfection efficiency by measuring the β-
galactosidase activity according to the manufacturer’s instructions [14-16]. 
Animal Experiments 
All animal experiments were conducted following guidelines specified by the 
Canadian Council of Animal Care. Protocols were approved by the Western 
University Animal Care and Veterinary Service. The investigations were in 
accordance with NIH publ. no. 85-23, revised 1996. 
Male C57BL/6 mice (20-25g), were obtained (Charles River, Wilmington, 
MA) and diabetes was induced by 1-2 intraperitoneal injection of streptozotocin 
(STZ) (65 mg/kg, in citrate buffer, pH 5.6). Age- and sex-matched mice were 
used as controls and given equal volumes of citrate buffer. db/db (Leprdb, DBA/J) 
mice (8 weeks, Jackson Laboratory, CA) were used as type 2 model of Diabetes. 
The animals were monitored daily [3, 18-23]. The animals were killed at 2 & 4 
months following the development of diabetes (n = 10/group). Retinal and renal 
cortical tissues were dissected out and snap frozen in liquid nitrogen. All tissues 
were stored at −80°C until further analysis. Urinary albumin (Exocell, 
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Philadelphia, PA) and serum creatinine (Arbor assays, Ann Arbor, MI) were 
measured as per the instructions.  
Sprague-Dawley rats (~175g, 6 weeks, male) were obtained (Charles 
River, Wilmington, MA) and diabetes was induced by a single intraperitoneal 
injection of streptozotocin (STZ) (65 mg/kg, in citrate buffer, pH 5.6). Control 
animals received equal volume of citrate buffer.  Diabetes was determined as a 
blood glucose level >20 mmol/l on 3 successive days (Abbott Diabetes Care, 
Alameda, CA). Animals were fed on a standard diet with water ad libitum and 
monitored daily [16, 18-23]. A group of diabetic rats (n=7/group) received weekly 
intravitreal injections of 1.5 µg miR-195 mimic or antagomir in lipofectamine 
reagent in one eye. The other eye received scrambled control. They were 
sacrificed one week after the fourth injection. Retinal tissues were collected, snap 
frozen and were stored at −80°C until further analysis. To assess intravitreal 
miRNA penetration efficiency DY547 (red fluorescent dye) tagged miRNA 
scramble transfection control (Dharmacon Inc., Chicago, IL) was injected 
intravitreally and retinal tissues were collected from sacrificed animals at 2 hr, 
4hr, 8hr and 24hr following injection and snap frozen [24].  Slides from the same 
sections were counterstained with H&E for orientation. 
SIRT1 transgenic mice (C57BL/6-Actbtm3.1(Sirt1)Npa/J), male, 8 weeks old 
were obtained (Jackson Laboratory, Bar Harbor, ME) and genotyped with Real 
Time RT-PCR. Diabetes was induced by 1-2 dose of intra-peritoneal injection of 
streptozotocin (STZ, 65 mg/kg in citrate buffer). Age and sex matched mice were 
used as controls and received equal volume of citrate buffer [3, 16, 18-23]. 
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Diabetes was defined in the animals with blood glucose level >20mmol/L on two 
consecutive days (Abbott Diabetes Care, Saint-Laurent, QC). The animals were 
fed on a standard rodent diet with water ad libitum and sacrificed after 2 months 
following the development of diabetes (n = 10/group). Urinary micro-albumin 
(Exocell, Philadelphia, PA) was measured as per the kit instructions. Retina and 
kidney tissues were collected and snap frozen in liquid nitrogen for histology. All 
tissues were stored at −80°C until further analysis.  
In situ Hybridization & Immunohistochemistry 
A 5' and 3' double DIG-labelled custom-made mercury LNA™ miRNA detection 
probes (Exiqon, Vedbaek, Denmark) were used to detect miR-195 expression 
using in situ hybridization(ISH) Kit (Biochain Institute, Hayward, CA) in retinal 
tissue sections. Scrambled probe and no-probe were used as controls [14-16, 
25]. IgG stainings were performed on frozen retinal sections using anti-rat IgG 
(ebioscience, Sandiego, CA) with hematoxylin counterstain [14-16]. 
Quantification was done in a masked fashion using an arbitrary scale (0 = no 
extravascular stain of retina, 1 = mild extravascular stain,   2 = moderate 
extravascular stain,   3 = marked extravascular stain).  
SA β-gal staining for senescence 
Cells or frozen tissue sections were fixed and stained with SA β- gal staining 
according to the manufacturer’s instructions (abcam, Cambridge, MA). In short, 
cells or frozen tissue sections were washed with PBS and fixed with fixative 
solution for 10-15 minutes at room temperature. Following two washes with PBS 
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cells/slides were covered in staining solution and incubated overnight at 37oC. 
For long-term storage of the stained plates/slides, the staining solution was 
removed and overlaid with 70% glycerol and stored at 4oC. Tissue slides were 
counterstained with H&E staining for orientation purpose [26]. 
Phase contrast and fluorescent microscopy   
From each specimen, positive (blue) cells were photographed with phase 
contrast inverted microscope using SPOT Basic software (Meiji Techno, TC5400, 
Santa Clara, CA). Morphometrical analysis of the images was done by ImageJ 
software (NIH, Bethesda, MD). They were counted per 10 microscopic fields at 
20X magnification and presented as % of total number of cells.  
Images of the tissue slides were recorded by an Olympus BX51 
microscope (Olympus, Center Valley, PA) with Northern Eclipse software (Empix 
Inc, Cheektowaga, NY).Tissue slides were quantified based on staining intensity 
[27] at 60X magnification. Quantification of SA-β-Gal intensity was done in a 
masked fashion using an arbitrary scale (0 = no stain, 1 = focal weak stain,   2 = 
multifocal moderate stain,   3 = multifocal intense stain). Fluorescent 
microscopies of frozen retinal sections were performed with TRITC filter at 20X 
magnification.   
Total ROS/RNS and Intracellular LDH analysis 
Total ROS/RNS level in the EC lysates/tissue homogenates were measured as 
per the manufacturer instructions using a commercially available kit (Cell Biolabs 
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Inc., San Diego, CA). The plates were read with a fluorescent plate reader 
(Biotek, Winooski, VT) at excitation 480 nm and emission 530 nm.  Total protein 
concentrations were measured by BCA protein assay kit (Pierce, Rockford, IL). 
Quantification of intracellular lactate dehydrogenase (LDH) in the cell lysates was 
used as an additional measure of cell growth. The assay was conducted as per 
the manufacturer instruction (Caymen Chemical, Ann Arbor, MI). 
MnSOD & FN ELISA 
MnSOD ELISA was done [3] on cell lysate and tissue homogenate as per the 
manufacturer instruction from a commercially available kit (abcam, Cambridge, 
MA). Fifty µl sample is added to each pre antibody coated wells and sealed and 
incubated for 2 hours at RT. Following 3 wash 50 µl detection antibody is added 
to each well and incubated for 1 hour. After 3 more washes 50 µl of HRP 
conjugate is added to each well and incubated another hour. Following 5 wash 
100 µl developing solution is added and upon colour development 100 µl of stop 
solution is added to each well. The plate is read at 450 nm using a plate reader 
(Multiskan, Thermo Scientific, Burlington, ON). Total protein concentrations were 
measured by BCA protein assay kit (Pierce, Rockford, IL). ELISA for FN was 
performed using commercially available kits for human FN (Millipore, Billerica, 
MA), rat FN (Kamiya Biomedical, Seattle, WA), mice FN (abcam, Toronto, ON) 
according to the manufacturers’ instructions [15, 16]. The plates were read at 450 
nm using a plate reader (Multiskan, Thermo Fisher, Canada). 
Nuclear fraction isolation 
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Nucleuar fractions were isolated from ECs and tissues as per the kit instruction 
(Active Motif, Carlsbad, USA). Briefly media was aspirated out of the flasks and 
washed with 5 ml ice cold PBS/Phosphatase Inhibitors. Another 3 ml of ice cold 
PBS/Phosphatase Inhibitor solution was added to the cells. Cells were gently 
scrapped and transferred to a pre chilled 15 ml conical tube and centrifuged for 5 
minute at 500 rpm at 4OC. The cell pellet was resuspended in 500 µl 1X 
hypotonic buffer and incubated on ice for 15 minute following mixing. Following 
this 25 µl of detergent was added, vortexed and centrifuged at 14000 x g for 30 
seconds at 4oC. The supernatant containing the cytoplasmic fraction was 
separated following which the nuclear pellet was resuspended in 50 µl of 
complete lysis buffer and vortexed for 10 seconds. Following 30 minute 
incubation on ice on a shaker the suspension was centrifuged for 10 minutes at 
14000 x g in a microcentrifuge precooled at 4oC. The supernatant containing the 
nuclear fraction was collected [1, 3]. Fresh tissue sections were cut and weighed 
washed in 3 ml (per gram tissue) ice cold 1X hypotonic buffer supplemented with 
DTT and detergent and homogenized. Following incubation on ice for 15 minute 
sample was centrifuged for 10 minute at 850 x g and pellet collected. Nuclear 
extraction of the pellet was done as per the protocol of the cells described above. 
Protein concentrations in the samples were measured by BCA protein assay 
(Pierce, Rockford, IL).  
FOXO1 DNA binding activity measurement 
FOXO1 DNA binding ELISA was conducted [3] on the collected nuclear fraction 
as per the manufacturer’s instruction (Active Motif, Carlsbad, CA). In short 10 ul 
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diluted nuclear extract samples (2-20 ug protein concentration) were added to 
oligonucleotide coated plates. The 96 well plate was sealed and incubated for 1 
hr at room temperature following which the plate was washed 5 times with wash 
buffer and 100 µl primary antibody (FOXO1) was added to each well. Following 1 
hr of incubation at RT the plate was washed 5 times and 100 µl anti IgG HRP 
conjugate antibody was added to each well. After 1 hr incubation plate was 
washed 5 times and 100 µl developing solution was added to each well. As color 
developed stop solution was added. The plates were read at 450 nm using a 
plate reader (Multiskan, Thermo Fisher, Canada). 
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Mortuza R, Chakrabarti S (2013). Glucose-induced cell signaling in the 
pathogenesis of diabetic cardiomyopathy. Heart Failure Reviews 19(1):75-86  
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Mortuza R, Chen S, Feng B, Sen S, Chakrabarti S (2013). High glucose induced 
alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO 
regulated pathway. PLoS ONE 8(1): e54514 
Mortuza R, Biao Feng, Chakrabarti S (2013). miR-195 regulates accelerated 
endothelial aging in diabetes through SIRT1. Diabetes, 62:A1-98 
Mortuza R, Chen S, Feng B, Chakrabarti S (2012). Glucose-induced SIRT 
mediated alterations in microvascular endothelial cells. Canadian Journal of 
Diabetes, 36(5):s50 
Mortuza R, Feng B, Chen S, Chakrabarti S (2011). Hyperglycemia mediated 
accelerated aging in diabetes. Diabetes 60: A442-521   
Mortuza R, Feng B, Chen S, Chakrabarti S (2011). Association of miR-9 with 
SIRT1 expression in chronic diabetic complications. Canadian Journal of 
Diabetes, 35:A403     
 
INVITED LECTURE/PRESENTATION 
2013-06 73rd Scientific Sessions, American Diabetes Association, Chicago, 
IL, USA.    Title: miR-195 regulated accelerated endothelial aging in diabetes 
through SIRT1. 
 
OTHER PROFESSIONAL PRESENTATIONS (Workshops, Symposia, 
Regional meetings, Research Days) 
Mortuza R, Biao Feng, Chakrabarti S (2013). miR-195 regulates accelerated 
endothelial aging in diabetes through SIRT1. London Health Research Day, 
London, ON 
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Mortuza R, Chakrabarti S (2012). Glucose induced SIRT mediated alterations in 
microvascular endothelial cells. Diabetes research day, Lawson Health 
Research Institute, London, ON 
Mortuza R, Feng B, Chen S, Chakrabarti S (2011). Association of miRNA9 with 
SIRT1 in chronic diabetic complications. Pathology research day, Western 
University, London, ON 
Mortuza R, Feng B, Chen S, Chakrabarti S (2011). Hyperglycemia accelerates 
aging in vascular endothelial cells in diabetes. Annual Interdisciplinary 
Research Event, Centre for Population, Health & Aging, Western University, 
London, ON 
Mortuza R, Feng B, Chen S, Chakrabarti S (2010). Role of Sirtuins on glucose 
induced endothelial dysfunction. Margaret Moffat Research Day, Western 
University, London, ON 
Mortuza R, Rutter M, Griffin A, Post M (2004).  Role of PitX2 transgenic factors 
on fetal lung development. Hospital for Sick Children, Toronto, ON 
Mortuza R, Rutter M, Griffin A, Post M (2004).  Neonatal lung development and 
related complications in premature newborns. Department of Laboratory 
Medicine & Pathobiology, University of Toronto, Toronto, ON  
Mortuza R, Ravichandiran K, Agur A (2004). Computerized 3D construction of 
bone, muscle and tendon architecture of human forearm. Department of 
Surgery, University of Toronto, Toronto, ON 
 
TEACHING EXPERIENCES (Undergraduate) 
2013   Teaching Assistant, Genetics 2581B, Dept.of Biology, Western 
University, London, ON   
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2012   Teaching Assistant, Biology for Science II 1002B, Dept. of Biology, 
Western University, London, ON   
2012   Teaching Assistant, General Biology II 1202B, Dept. of Biology, 
Western University, London, ON   
 
WORK EXPERIENCES 
2009-2014  Graduate Research Assistant -Department of Pathology, Western 
University, London, ON 
2007-2010    Lab Manager- CRS Division, 
                      KGK Synergize Inc., London, ON  
2005-2007    Toxicologist-Biological Activity Department 
                      Labstat International Inc, Kitchener, ON 
2005              Microbiologist (Co-op), Microbiology Department 
            Maxxam Analytics Inc, Mississauga, ON                       
2004   Research Assistant  
              Hospital for Sick Children, Toronto, ON 
2003              Research Student  
                      DEPARTMENT OF SURGERY, University of Toronto, ON 
  
DISTINCTIONS, HONOURS, SCHOLARSHIPS 
2011-2014 Western Graduate Research Scholarship, UWO, London, ON 
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2011, 2013 Dutkevich Memorial Foundation Award, Department of Pathology, 
UWO, London, ON 
2012 Nominated, Queen Elizabeth II Graduate Scholarships in Science 
and Technology, Ministry of Training, Colleges, and Universities, 
ON 
2004 Graduated with distinction from U of T, Toronto, ON  
2003 Undergraduate Summer Student Research Award, Department of 
Laboratory Medicine & Pathobiology, U of T, Toronto, ON 
2001  Millennium Scholarship, University of Toronto, Toronto, ON 
 
COMMUNITY INVOLVEMENT, COMMITTEES, SOCIETIES & OTHER 
ACTIVITIES 
2011-2012 Volunteered and served as a councillor (2011-2012) at the 
Society of Graduate  Students (SOGS) on behalf of the 
department of pathology graduate students , Western University, 
London, ON  
2009 Volunteered as a coordinator (2009) at the Toronto Man to Man 
Prostate Cancer Support Group on a research related to effect of 
Vit D on prostate cancer, Toronto, ON 
2007-2011 Volunteered as a member (2007-2011) of the Safety Task Force 
at the South Street Hospital, London Health Sciences Centre, 
London, ON 
2007 Volunteered as a member (2007) of the Health and Wellness 
Committee to organize various social activities for the betterment 
of employees at Labstat Internationl ULC, Kitchener, ON 
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2006 Volunteered as a member (2006) of the Ergonomic Committee 
for helping the employees injured at work at Labstat Internationl 
ULC, Kitchener, ON 
2001 Volunteer summer student (2001) at the Respiratory 
Physiology Research lab at the University of Toronto, Toronto, 
ON 
2002 Life time member of Golden Key International Honorary Society, 
Canada  
2004 Member of Laboratory Medicine & Pathobiology Alumni 2004, 
University of Toronto, ON 
     
